柿坂 達彦 (カキサカ タツヒコ)

医学研究院 外科系部門 外科学分野講師
北海道大学病院講師
Last Updated :2025/06/07

■研究者基本情報

学位

  • 医学博士, 北海道大学

Researchmap個人ページ

研究キーワード

  • 発現解析

研究分野

  • ライフサイエンス, 腫瘍診断、治療学
  • ライフサイエンス, 消化器外科学

担当教育組織

■経歴

経歴

  • 2014年
    北海道大学, 大学病院

■研究活動情報

論文

  • Site-Specific O-Glycosylation in Oncofetal Fibronectin IIICS Domain Creates Cancer Stage-Specific Biomarkers.
    Nozomi Hirane, Yasuhiro Yokoi, Aiko Kobayashi, Misaki Yamada, Taiki Konno, Hiroyuki Kumeta, Hajime Wakui, Michiru Otaki, Yoshiaki Miura, Tatsuhiko Kakisaka, Toshiya Kamiyama, Akinobu Taketomi, Kazuhiro Nouso, Satoshi Kimura, Shin-Ichiro Nishimura
    Journal of the American Chemical Society, 147, 14, 12170, 12184, 2025年04月09日, [国際誌]
    英語, 研究論文(学術雑誌), Despite the pathological importance of oncofetal fibronectin isoforms associated with cancer cell progression and metastasis, our understanding of the structural and molecular details that occurred in this abundant and ubiquitous extracellular matrix component remains largely unknown. Here, we communicate that site-specific O-glycosylation in the oncofetal fibronectin creates cancer stage-specific serum biomarkers for hepatocellular carcinoma (HCC) by quantitative MS-based glycoproteomic approach. Selective reaction monitoring (SRM) using a structure-defined synthetic glycopeptide library enabled absolute quantitation of the targeted label-free tryptic fragments bearing cancer-relevant O-glycans derived from the type III homology connective segment (IIICS) domain of the oncofetal fibronectin (onfFN) in the sera of HCC patients and healthy controls. We found site-specific O-glycoform alteration from T/sialyl T antigens to Tn/sialyl Tn antigens at the consecutive threonine residues 2155Thr-Thr-Ala2157 within this fragment during cancer progression. Surprisingly, this dynamic glycoform alteration is observed specifically in the patient sera diagnosed newly as stage 2-4 groups not in the normal control and stage 1 patient groups. Our results provide compelling evidence that site-specific glycoform changes observed in the onfFN IIICS domain during the tumor proliferation elaborate new class cancer stage-relevant "dynamic epitopes" as highly potential cancer diagnostic and therapeutic targets.
  • Normal tissue complication probability model for severe radiation-induced lymphopenia in patients with pancreatic cancer treated with concurrent chemoradiotherapy
    Fuki Koizumi, Norio Katoh, Takahiro Kanehira, Yasuyuki Kawamoto, Toru Nakamura, Tatsuhiko Kakisaka, Miyako Myojin, Noriaki Nishiyama, Akio Yonesaka, Manami Otsuka, Rikiya Takashina, Hideki Minatogawa, Hajime Higaki, Yusuke Uchinami, Hiroshi Taguchi, Kentaro Nishioka, Koichi Yasuda, Naoki Miyamoto, Isao Yokota, Keiji Kobashi, Hidefumi Aoyama
    Physics and Imaging in Radiation Oncology, 100690, 100690, Elsevier BV, 2024年12月
    研究論文(学術雑誌)
  • 分子標的薬がBCLC stage Cの肝細胞癌の手術成績に与えた影響               
    旭 よう, 柿坂 達彦, 折茂 達也, 長津 明久, 相山 健, 脇坂 和貴, 志智 俊介, 武冨 紹信
    日本癌治療学会学術集会抄録集, 62回, O16, 5, (一社)日本癌治療学会, 2024年10月
    英語
  • Improved survival outcome of curative liver resection for Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma in the era of tyrosine kinase inhibitors.
    Yoh Asahi, Tatsuhiko Kakisaka, Toshiya Kamiyama, Tatsuya Orimo, Shingo Shimada, Akihisa Nagatsu, Takeshi Aiyama, Yuzuru Sakamoto, Kazuki Wakizaka, Shunsuke Shichi, Hirofumi Kamachi, Akinobu Taketomi
    Hepatology research : the official journal of the Japan Society of Hepatology, 2024年07月26日, [国際誌]
    英語, 研究論文(学術雑誌), AIM: This study was undertaken to evaluate the outcome of curative liver resection, (LR) of Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma (BCLC-C HCC) after tyrosine kinase inhibitors (TKIs) became approved as a treatment option for recurrent lesions. METHODS: Sixty-seven patients with BCLC-C HCC who underwent curative LR were enrolled in this study. The patients were classified into two groups according to whether LR was performed before (n = 24) or after (n = 43) TKI approval ("beforeTKI" and "afterTKI" group, respectively). RESULTS: There was no difference in the median disease-free survival time after LR between the beforeTKI and afterTKI groups (5.6 and 7.1 months, respectively; p = 0.435). However, the median survival time after LR was longer in the afterTKI than beforeTKI group (42.7 and 14.9 months, respectively; p = 0.022). Univariate and multivariate analyses showed that the date of LR was the only independent factor affecting postresection survival. When the patients were limited to those with recurrence, there were no differences in the recurrence pattern or progression of HCC at the time of recurrence between the two groups. The only difference in the treatment distribution was the administration of TKIs (14 of 34 patients in afterTKI group and only 1 of 19 patients in beforeTKI group, p < 0.001). CONCLUSION: These data suggest that TKI therapy for recurrent BCLC-C HCC is associated with improved overall survival. Thus, LR could be a promising option for BCLC-C HCC in the current era of TKI therapy.
  • Diacylglycerol kinase alpha is a proliferation marker of intrahepatic cholangiocarcinoma associated with the prognosis.
    Shunsuke Shichi, Ko Sugiyama, Yoh Asahi, Chisato Shirakawa, Hiroki Nakamoto, Saori Kimura, Kazuki Wakizaka, Takeshi Aiyama, Akihisa Nagatsu, Tatsuya Orimo, Tatsuhiko Kakisaka, Akinobu Taketomi
    Cancer medicine, 13, 9, e7238, 2024年05月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) has a high recurrence rate and a poor prognosis. Thus, the development of effective treatment and prognostic biomarkers is required. High expression of diacylglycerol kinase alpha (DGKα) is a prognostic factor for the recurrence of hepatocellular carcinoma. However, the relationship between DGKα expression and prognosis in ICC has not been reported. METHODS: Immunohistochemistry (IHC) with anti-DGKα antibody was performed on surgical specimens of ICC (n = 69). First, DGKα expression in cancer cells was qualitatively classified into four groups (-, 1+, 2+, 3+) and divided into two groups (DGKα- and DGKα+1 + to 3+). The relationship between clinical features and DGKα expression was analyzed. Second, Ki-67 expression was evaluated as a cell proliferation marker. The number of Ki-67-positive cells was counted, and the relationship with DGKα expression was examined. RESULTS: DGKα IHC divided the patients into a DGKα+ group (1+: n = 15; 2+: n = 5; 3+: n = 5) and a DGKα- group (-: n = 44). In the DGKα+ group, patients were older and had advanced disease. Both overall survival and recurrence-free survival (RFS) were significantly worse in the DGKα+ patients. DGKα+ was identified as an independent prognostic factor for RFS by multivariate analysis. Furthermore, the number of Ki-67-positive cells increased in association with the staining levels of DGKα. CONCLUSION: Pathological DGKα expression in ICC was a cancer proliferation marker associated with recurrence. This suggests that DGKα may be a potential therapeutic target for ICC.
  • 結腸がん切除手術における手縫い吻合と器械吻合の実施状況と臨床的アウトカムに関するDPCデータを用いた研究               
    海老沼 翔太, 國澤 進, 愼 重虎, 伏見 清秀, 市川 伸樹, 吉田 雅, 柿坂 達彦, 本間 重紀, 武冨 紹信, 今中 雄一
    日本外科学会定期学術集会抄録集, 124回, SF, 5, (一社)日本外科学会, 2024年04月
    日本語
  • 結腸がん切除手術における手縫い吻合と器械吻合の実施状況と臨床的アウトカムに関するDPCデータを用いた研究               
    海老沼 翔太, 國澤 進, 愼 重虎, 伏見 清秀, 市川 伸樹, 吉田 雅, 柿坂 達彦, 本間 重紀, 武冨 紹信, 今中 雄一
    日本外科学会定期学術集会抄録集, 124回, SF, 5, (一社)日本外科学会, 2024年04月
    日本語
  • 肝内胆管癌における術前リンパ節転移評価およびリンパ節郭清の臨床的意義               
    志智 俊介, 脇坂 和貴, 相山 健, 長津 明久, 折茂 達也, 柿坂 達彦, 武冨 紹信
    日本外科学会定期学術集会抄録集, 124回, PS, 1, (一社)日本外科学会, 2024年04月
    日本語
  • 肝再生分子機構におけるDGKαの新しい機能解析               
    中本 裕紀, 鈴木 琢士, 白川 智沙斗, 志智 俊介, 長津 明久, 折茂 達哉, 柿坂 達彦, 北村 秀光, 武冨 紹信
    日本外科学会定期学術集会抄録集, 124回, PS, 7, (一社)日本外科学会, 2024年04月
    日本語
  • 再肝切除症例に対する低侵襲手術の工夫と注意点               
    長津 明久, 柿坂 達彦, 志智 俊介, 脇坂 和貴, 相山 健, 折茂 達也, 武冨 紹信
    日本外科学会定期学術集会抄録集, 124回, PS, 6, (一社)日本外科学会, 2024年04月
    日本語
  • 切除不能肝細胞癌に対してアテゾリズマブ・ベバシズマブ併用療法後にconversion surgeryを施行し得た3症例               
    小林 正幸, 相山 健, 柿坂 達彦, 折茂 達也, 長津 明久, 脇坂 和貴, 志智 俊介, 清水 亜衣, 大川 紘弥, 武冨 紹信
    日本外科学会定期学術集会抄録集, 124回, PS, 4, (一社)日本外科学会, 2024年04月
    日本語
  • Child-Pugh分類Bの肝細胞癌に対する肝切除術の検討               
    脇坂 和貴, 志智 俊介, 相山 健, 長津 明久, 折茂 達也, 柿坂 達彦, 武冨 紹信
    日本外科学会定期学術集会抄録集, 124回, PS, 4, (一社)日本外科学会, 2024年04月
    日本語
  • 当科における胆道癌に対する肝膵同時切除症例の臨床病理学的検討               
    柿坂 達彦, 折茂 達也, 長津 明久, 相山 健, 脇坂 和貴, 志智 俊介, 武冨 紹信
    日本外科学会定期学術集会抄録集, 124回, PS, 7, (一社)日本外科学会, 2024年04月
    日本語
  • 術前に肝硬化性血管腫との鑑別に難渋した細胆管細胞癌の1切除例               
    森越 健之介, 脇坂 和貴, 志智 俊介, 相山 健, 長津 明久, 折茂 達也, 柿坂 達彦, 武冨 紹信
    日本外科学会定期学術集会抄録集, 124回, RS, 4, (一社)日本外科学会, 2024年04月
    日本語
  • Treatment of delayed pancreatic fistula associated with anastomosis breakdown after pancreaticoduodenectomy using percutaneous interventions.
    Reimi Suzuki, Yuji Konishi, Kai Makino, Yosuke Wakui, Kazuhiro Mino, Hideki Kawamura, Ryo Morita, Tatsuhiko Kakisaka, Daisuke Abo, Akinobu Taketomi
    Clinical journal of gastroenterology, 17, 2, 356, 362, 2024年04月, [国内誌]
    英語, 研究論文(学術雑誌), We here present a rare case of development of a postoperative pancreatic fistula and breakdown of the pancreaticojejunal anastomosis 8 months after pancreaticoduodenectomy. A 70-year-old man underwent pancreaticoduodenectomy for distal cholangiocarcinoma and initially recovered well. However, 8 months later, he developed abdominal pain and distention and was admitted to our institution with suspected pancreatitis. On the 17th day of hospitalization, he suddenly bled from the jejunal loop and a fluid collection was detected near the pancreaticojejunal anastomosis site. The fluid collection was drained percutaneously. Subsequent fistulography confirmed breakdown of the pancreaticojejunal anastomosis. Considering the patient's overall condition and the presence of postoperative adhesions, we decided to manage him conservatively. An additional drain tube was placed percutaneously from the site of the anastomotic breakdown into the lumen of the jejunum, along with the tube draining the fluid collection, creating a completely new fistula. This facilitated the flow of pancreatic fluid into the jejunum and was removed 192 days after placement. During a 6-month follow-up, there were no recurrences of pancreatitis or a pancreatic fistula. This case highlights the efficacy of percutaneous drainage and creation of an internal fistula as a management strategy for delayed pancreatic fistula and anastomotic breakdown following pancreaticoduodenectomy.
  • Expression of Wnt5a and ROR2, Components of the Noncanonical Wnt-Signaling Pathway, is Associated with Tumor Differentiation in Hepatocellular Carcinoma.
    Kazuki Wakizaka, Toshiya Kamiyama, Tatsuhiko Kakisaka, Tatsuya Orimo, Akihisa Nagatsu, Takeshi Aiyama, Shunsuke Shichi, Akinobu Taketomi
    Annals of surgical oncology, 31, 1, 262, 271, 2024年01月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Wnt5a is the key ligand of the noncanonical Wnt pathway, and receptor tyrosine kinase-like orphan receptor 2 (ROR2) is a receptor associated with Wnt5a. The association between the noncanonical Wnt-signaling pathway and carcinogenesis in hepatocellular carcinoma (HCC) is unclear. This study investigated the significance of ROR2 expression in HCC. METHODS: The study examined ROR2 expression in liver cancer cell lines. Immunohistochemical staining of ROR2 was performed on 243 resected HCC specimens. The study investigated ROR2 expression and its association with clinicopathologic factors and prognosis. RESULTS: Findings showed that ROR2 was expressed in well-differentiated Huh7 and HepG2 cells, but not in poorly differentiated HLE and HLF cells. Expression of ROR2 was positive in 147 (60.5%) and negative in 96 (39.5%) HCC specimens. A significant association was shown between ROR2 negativity and high alpha-fetoprotein (AFP) level (P = 0.006), poor differentiation (P = 0.015), and Wnt5a negativity (P = 0.024). The 5-year overall survival (OS) rate for the ROR2-negative group (64.2 %) tended to be worse than for the ROR2-positive group (73.8%), but the difference was not significant (P = 0.312). The 5-year OS rate was 78.7% for the ROR2+Wnt5a+ group, 71.3 % for the ROR2+Wnt5a- group, 80.8% for the ROR2-Wnt5a+ group, and 60.5 % for the ROR2-Wnt5a- group. The OS in the ROR2-Wnt5a- group was significantly poorer than in the ROR2+Wnt5a+ group (P = 0.030). The multivariate analysis showed that Wnt5a-ROR2- was an independent prognostic factor (hazard ratio, 2.058; 95% confidence interval, 1.013-4.180; P = 0.045). CONCLUSIONS: The combination of ROR2 and Wnt5a may be a prognostic indicator for HCC. The Wnt5a/ROR2 signal pathway may be involved in the differentiation of HCC. This pathway may be a new therapeutic target for HCC.
  • Real-time tumor-tracking radiotherapy with SyncTraX for primary liver tumors requiring isocenter shift†.
    Yusuke Uchinami, Naoki Miyamoto, Daisuke Abo, Ryo Morita, Koji Ogawa, Tatsuhiko Kakisaka, Ryusuke Suzuki, Tomohiko Miyazaki, Hiroshi Taguchi, Norio Katoh, Hidefumi Aoyama
    Journal of radiation research, 2023年11月22日, [国際誌]
    英語, 研究論文(学術雑誌), The SyncTraX series enables real-time tumor-tracking radiotherapy through the real-time recognition of a fiducial marker using fluoroscopic images. In this system, the isocenter should be located within approximately 5-7.5 cm from the marker, depending on the version, owing to the limited field of view. If the marker is placed away from the tumor, the isocenter should be shifted toward the marker. This study aimed to investigate stereotactic body radiotherapy (SBRT) outcomes of primary liver tumors treated with SyncTraX in cases where the isocenter was shifted marginally or outside the planning target volume (PTV). Twelve patients with 13 liver tumors were included in the analysis. Their isocenter was shifted toward the marker and was placed marginally or outside the PTV. The prescribed doses were generally 40 Gy in four fractions or 48 Gy in eight fractions. The overall survival (OS) and local control (LC) rates were calculated using the Kaplan-Meier method. All patients completed the scheduled SBRT. The median distance between the fiducial marker and PTV centroid was 56.0 (interquartile range [IQR]: 52.7-66.7) mm. By shifting the isocenter toward the marker, the median distance between the marker and isocenter decreased to 34.0 (IQR: 33.4-39.7) mm. With a median follow-up period of 25.3 (range: 6.9-70.0) months, the 2-year OS and LC rates were 100.0% (95% confidence interval: 100-100). An isocenter shift makes SBRT with SyncTraX feasible in cases where the fiducial marker is distant from the tumor.
  • 【COVID-19のみならず!肝胆膵と感染症】肝胆膵診療での感染症各論 日常臨床における肝エキノコックス症               
    相山 健, 柿坂 達彦, 折茂 達也, 長津 明久, 脇坂 和貴, 志智 俊介, 岡田 宏美, 武冨 紹信
    肝胆膵, 87, 3, 287, 294, (株)アークメディア, 2023年09月
    日本語
  • Lymphaticovenous anastomosis for treatment of refractory chylous ascites: A case report.
    Shoichi Tsuzaka, Takeshi Aiyama, Hirofumi Kamachi, Tatsuhiko Kakisaka, Tatsuya Orimo, Akihisa Nagatsu, Yoh Asahi, Taku Maeda, Toshiya Kamiyama, Akinobu Taketomi
    Microsurgery, 43, 6, 606, 610, 2023年09月, [国際誌]
    英語, Chylous ascites, the leakage of lymphatic fluid into the abdominal cavity caused by lymphatic fluid stasis or lymphatic vessel damage, can be treated by lymphaticovenous anastomosis (LVA). We report rarely performed abdominal LVA to treat a case of refractory ascites possibly caused by ligation of the thoracic duct and pleurodesis in a man aged 60 years requiring weekly ascites drainage. Ligation was abandoned because the leakage site was not determined. The greater omentum (GO) was generally edematous and showed lymphatic effusion by gross appearance, and was considered suitable for LVA. We performed once LVA in the lymphatic vessels and veins of the GO using common microsurgical instrumentation and lateral anastomosis. Lymphatic vessels in the omentum were dilated to 2-3 mm, and LVA was simple. After LVA, GO edema improved. Postoperatively, the patient developed paralytic ileus, which improved within a few days, and the patient was discharged without any increase in ascites after starting to diet. One year post-surgery, there was no recurrence of ascites. LVA at the GO may be effective for the treatment of refractory chylous ascites because of its absorptive lymphatic draining capabilities and large transverse vessels.
  • 肝細胞癌におけるWntシグナル伝達経路受容体ROR2の発現についての検討               
    脇坂 和貴, 志智 俊介, 相山 健, 長津 明久, 折茂 達也, 柿坂 達彦, 三橋 智子, 武冨 紹信
    日本消化器外科学会総会, 78回, P100, 6, (一社)日本消化器外科学会, 2023年07月
    日本語
  • 【肝胆膵外科手術における術中トラブルシューティング】肝臓 開腹肝切除における肝門操作時の門脈・肝動脈損傷への対処法
    長津 明久, 柿坂 達彦, 折茂 達也, 相山 健, 脇坂 和貴, 志智 俊介, 武冨 紹信
    外科, 85, 8, 868, 873, (株)南江堂, 2023年07月
    日本語
  • 腹部手術後門脈狭窄/閉塞に対する門脈ステント留置による血液検査データ変化に関する検討               
    木野田 直也, 阿保 大介, 木村 輔, 作原 祐介, 藤井 宝顕, 加藤 大祐, 高橋 文也, 森田 亮, 折茂 達也, 柿坂 達彦, 中村 透, 平野 聡, 箕輪 和行, 工藤 與亮
    日本インターベンショナルラジオロジー学会雑誌, 38, Suppl., 205, 205, (一社)日本インターベンショナルラジオロジー学会, 2023年04月
    日本語
  • 肝エキノコックス症による右肝静脈狭窄に対してcovered stentを留置した一例               
    渡辺 祈一, 阿保 大介, 森田 亮, 木野田 直也, 高橋 文也, 加藤 大祐, 藤井 宝顕, 柿坂 達彦, 折茂 達也, 工藤 與亮
    日本インターベンショナルラジオロジー学会雑誌, 38, Suppl., 277, 277, (一社)日本インターベンショナルラジオロジー学会, 2023年04月
    日本語
  • 肝切除術後の門脈血栓症に対する治療の検討               
    脇坂 和貴, 相山 健, 長津 明久, 折茂 達也, 柿坂 達彦, 武冨 紹信
    日本外科学会定期学術集会抄録集, 123回, DP, 4, (一社)日本外科学会, 2023年04月
    日本語
  • 腹部手術後門脈狭窄/閉塞に対する門脈ステント留置による血液検査データ変化に関する検討               
    木野田 直也, 阿保 大介, 木村 輔, 作原 祐介, 藤井 宝顕, 加藤 大祐, 高橋 文也, 森田 亮, 折茂 達也, 柿坂 達彦, 中村 透, 平野 聡, 箕輪 和行, 工藤 與亮
    日本インターベンショナルラジオロジー学会雑誌, 38, Suppl., 205, 205, (一社)日本インターベンショナルラジオロジー学会, 2023年04月
    日本語
  • 肝エキノコックス症による右肝静脈狭窄に対してcovered stentを留置した一例               
    渡辺 祈一, 阿保 大介, 森田 亮, 木野田 直也, 高橋 文也, 加藤 大祐, 藤井 宝顕, 柿坂 達彦, 折茂 達也, 工藤 與亮
    日本インターベンショナルラジオロジー学会雑誌, 38, Suppl., 277, 277, (一社)日本インターベンショナルラジオロジー学会, 2023年04月
    日本語
  • Study of hepatic toxicity in small liver tumors after photon or proton therapy based on factors predicting the benefits of proton.
    Yusuke Uchinami, Norio Katoh, Daisuke Abo, Ryo Morita, Hiroshi Taguchi, Yoshihiro Fujita, Takahiro Kanehira, Ryusuke Suzuki, Naoki Miyamoto, Seishin Takao, Taeko Matsuura, Takuya Sho, Koji Ogawa, Tatsuya Orimo, Tatsuhiko Kakisaka, Keiji Kobashi, Hidefumi Aoyama
    The British journal of radiology, 96, 1144, 20220720, 20220720, 2023年01月12日, [国際誌]
    英語, 研究論文(学術雑誌), OBJECTIVES: In a previous study of hepatic toxicity, the following three factors were identified to predict the benefits of proton beam therapy (PBT) for hepatocellular carcinomas (HCC) with a maximum diameter of ≤5 cm and Child-pugh grade A (CP-A): number of tumors (one vs ≥2), the location of tumors (hepatic hilum or others), and the sum of the diameters of lesions. The aim of this study is to analyze the association between these three factors and hepatic toxicity. METHODS: We retrospectively reviewed patients of CP-A treated with PBT or photon stereotactic body radiotherapy (X-ray radiotherapy, XRT) for HCC ≤5 cm. For normal liver dose, the V5, V10, V20 (volumes receiving 5, 10, and 20 Gy at least), and the mean dose was evaluated. The albumin-bilirubin (ALBI) and CP score changes from the baseline were evaluated at 3 and 6 months after treatment. RESULTS: In 89 patients (XRT: 48, PBT: 41), those with two or three (2-3) predictive factors were higher normal liver doses than with zero or one (0-1) factor. In the PBT group, the ALBI score worsened more in patients with 2-3 factors than those with 0-1 factor, at 3 months (median 0.26 vs 0.02, p = 0.032) and at 6 months (median: 0.35 vs 0.10, p = 0.009). The ALBI score change in the XRT group and CP score change in either modality were not significantly different in the number of predictive factors. CONCLUSIONS: The predictive factor numbers predicted the ALBI score change in PBT but not in XRT. ADVANCES IN KNOWLEDGE: This study suggest that the number of predictive factors previously identified (0-1 vs 2-3) were significantly associated with dosimetric parameters of the normal liver in both modalities. In the proton group, the number of predictive factors was associated with a worsening ALBI score at 3 and 6 months, but these associations were not found in the photon SBRT group.
  • Preoperative Sustained C-Reactive Protein Elevation Impairs Patient Survival after Liver Resection for Perihilar Cholangiocarcinoma
    Tatsuhiko Kakisaka
    Journal of the American College of Surgeons, 2023年
    研究論文(学術雑誌)
  • 肝切除におけるナビゲーション 3次元画像解析システムを応用した肝切除               
    折茂 達也, 柿坂 達彦, 長津 明久, 相山 健, 脇坂 和貴, 武冨 紹信
    日本臨床外科学会雑誌, 83, 増刊, S170, S170, 日本臨床外科学会, 2022年10月
    日本語
  • ASO Visual Abstract: Hepatectomy is Beneficial for Select Patients with Multiple Hepatocellular Carcinomas.
    Tatsuya Orimo, Toshiya Kamiyama, Tatsuhiko Kakisaka, Akihisa Nagatsu, Yoh Asahi, Takeshi Aiyama, Hirofumi Kamachi, Akinobu Taketomi
    Annals of surgical oncology, 29, 13, 8448, 8448, 2022年09月30日, [国際誌]
    英語, 研究論文(学術雑誌)
  • Hepatectomy is Beneficial in Select Patients with Multiple Hepatocellular Carcinomas.
    Tatsuya Orimo, Toshiya Kamiyama, Tatsuhiko Kakisaka, Akihisa Nagatsu, Yoh Asahi, Takeshi Aiyama, Hirofumi Kamachi, Akinobu Taketomi
    Annals of surgical oncology, 29, 13, 8436, 8445, 2022年09月13日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: A single hepatocellular carcinoma (HCC) is a good indication for hepatic resection regardless of tumor size, but the surgical indications for cases with multiple HCCs remain unclear. METHODS: We retrospectively reviewed the outcomes of hepatectomies for Barcelona Clinic Liver Cancer (BCLC) stage 0, A, and B HCCs. We further subclassified stage A and B into A1 (single nodule <5 cm, or three or fewer nodules ≤3 cm), A2 (single nodule 5-10 cm), A3 (single nodule ≥10 cm), B1 (two to three nodules >3 cm), and B2 (four or more nodules). RESULTS: A total of 1088 patients were enrolled, comprising 88 stage 0, 750 stage A (A1: 485; A2: 190; A3: 75), and 250 stage B (B1: 166; B2: 84) cases. The 5-year overall survival (OS) rates for stage 0, A1, A2, A3, B1, and B2 patients were 70.4%, 74.2%, 63.8%, 47.7%, 47.5%, and 31.9%, respectively (p < 0.0001). Significant differences in OS were found between stages A1 and A2 (p = 0.0118), A2 and A3 (p = 0.0013), and B1 and B2 (p = 0.0050), but not between stages A3 and B1 (p = 0.4742). In stage B1 patients, multivariate analysis indicated that Child-Pugh B cirrhosis was the only independent prognostic factor for the OS outcome. CONCLUSIONS: A hepatectomy should be considered for multiple HCCs if the number of tumors is three or fewer, especially in patients with no cirrhosis or in Child-Pugh A cases, because the long-term results are equivalent to those for a single HCC.
  • Conversion surgery after lenvatinib treatment for multiple lung metastases from hepatocellular carcinoma
    Shunji Sano, Yoh Asahi, Toshiya Kamiyama, Tatsuhiko Kakisaka, Tatsuya Orimo, Akihisa Nagatsu, Takeshi Aiyama, Keizo Kazui, Hiroki Shomura, Shinya Ueki, Yuzuru Sakamoto, Chisato Shirakawa, Hirofumi Kamachi, Hirokazu Sugino, Tomoko Mitsuhashi, Akinobu Taketomi
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2022年08月
    英語, 研究論文(学術雑誌)
  • Impact of comorbid renal dysfunction in patients with hepatocellular carcinoma on long-term outcomes after curative resection.
    Yuzuru Sakamoto, Shingo Shimada, Toshiya Kamiyama, Ko Sugiyama, Yoh Asahi, Akihisa Nagatsu, Tatsuya Orimo, Tatsuhiko Kakisaka, Hirofumi Kamachi, Yoichi M Ito, Akinobu Taketomi
    World journal of gastrointestinal surgery, 14, 7, 670, 684, 2022年07月27日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. However, the number of patients with chronic kidney disease (CKD) is on the rise because of the increase in lifestyle-related diseases. AIM: To establish a tailored management strategy for HCC patients, we evaluated the impact of comorbid renal dysfunction (RD), as stratified by using the estimated glomerular filtration rate (EGFR), and assessed the oncologic validity of hepatectomy for HCC patients with RD. METHODS: We enrolled 800 HCC patients who underwent hepatectomy between 1997 and 2015 at our university hospital. We categorized patients into two (RD, EGFR < 60 mL/min/1.73 m2; non-RD, EGFR ≥ 60 mL/min/1.73 m2) and three groups (severe CKD, EGFR < 30 mL/min/1.73 m2; mild CKD, 30 ≤ EGFR < 60 mL/min/1.73 m2; control, EGFR ≥ 60 mL/min/1.73 m2) according to renal function as defined by the EGFR. Overall survival (OS) and recurrence-free survival (RFS) were compared among these groups with the log-rank test, and we also analyzed survival by using a propensity score matching (PSM) model to exclude the influence of patient characteristics. The mean postoperative observation period was 64.7 ± 53.0 mo. RESULTS: The RD patients were significantly older and had lower serum total bilirubin, aspartate aminotransferase, and aspartate aminotransferase levels than the non-RD patients (P < 0.0001, P < 0.001, P < 0.05, and P < 0.01, respectively). No patient received maintenance hemodialysis after surgery. Although the overall postoperative complication rates were similar between the RD and non-RD patients, the proportions of postoperative bleeding and surgical site infection were significantly higher in the RD patients (5.5% vs 1.8%; P < 0.05, 3.9% vs 1.8%; P < 0.05, respectively), and postoperative bleeding was the highest in the severe CKD group (P < 0.05). Regardless of the degree of comorbid RD, OS and RFS were comparable, even after PSM between the RD and non-RD groups to exclude the influence of patient characteristics, liver function, and other causes of death. CONCLUSION: Comorbid mild RD had a negligible impact on the prognosis of HCC patients who underwent curative hepatectomy with appropriate perioperative management, and close attention to severe CKD is necessary to prevent postoperative bleeding and surgical site infection.
  • Liver metastasis 13 years after the resection of a malignant triton tumor originating in the duodenum
    Keita Ohashi, Yoh Asahi, Toshiya Kamiyama, Tatsuhiko Kakisaka, Tatsuya Orimo, Akihisa Nagatsu, Yuzuru Sakamoto, Hirofumi Kamachi, Tomofumi Takagi, Takuya Otsuka, Tomoko Mitsuhashi, Shintaro Sugita, Tadashi Hasegawa, Akinobu Taketomi
    International Cancer Conference Journal, 11, 3, 178, 183, Springer Science and Business Media LLC, 2022年07月
    研究論文(学術雑誌)
  • 経皮経肝門脈右枝塞栓後にcoronavirus disease 2019に罹患した盲腸癌肝転移の治癒的切除例
    藤好 直, 柿坂 達彦, 松澤 文彦, 下國 達志, 木井 修平, 蔵谷 勇樹, 西川 眞, 森田 亮, 中西 勝也, 高木 智史, 高橋 昌宏
    日本消化器外科学会雑誌, 55, 6, 389, 398, (一社)日本消化器外科学会, 2022年06月
    日本語
  • A case of alveolar echinococcosis in the liver that ruptured into the pericardium treated by a combination of hepatectomy and albendazole.
    Yoichi Yamamoto, Yuzuru Sakamoto, Toshiya Kamiyama, Akihisa Nagatsu, Yoh Asahi, Tatsuya Orimo, Tatsuhiko Kakisaka, Hirofumi Kamachi, Takuya Otsuka, Tomoko Mitsuhashi, Akinobu Taketomi
    Surgical case reports, 8, 1, 63, 63, 2022年04月08日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Alveolar echinococcosis (AE) is a rare parasitic disease caused by the larva of Echinococcus multilocularis. It nearly always occurs in the liver, and cardiac involvement is extremely rare. Liver resection is the most effective intervention for AE because the only potentially curative treatment is removal of the lesion. Even when complete resection is not performed, long-term survival can be expected after surgical removal of most of the lesion with lifelong administration of albendazole (ABZ). CASE PRESENTATION: A 64-year-old man who lived in Hokkaido was referred to our hospital due to abnormalities in biliary enzymes. According to the findings from enhanced computed tomography and magnetic resource imaging of the abdomen, transthoracic echocardiography and serologic tests, he was diagnosed with hepatic AE with rupture into the pericardium. He underwent extended left hemi-hepatectomy with reconstruction of the inferior vena cava and opening of the pericardium with drainage as reduction surgery. Pathological examination revealed echinococcal infection in the pericardium as well as the liver. He started chemotherapy with 400 mg ABZ per Day 67 days after surgery. Although the surgical margin was positive in the pathological findings, he was alive 19 months later with no regrowth of the echinococcal lesion. CONCLUSION: AE with cardiac involvement is extremely rare. Even if the complete removal of cardiac-involved AE is not possible, surgical debulking with lifelong ABZ treatment can successfully manage the disease.
  • 分子標的薬時代後のBCLC stage C肝細胞癌の切除後成績の変化               
    旭 火華, 神山 俊哉, 柿坂 達彦, 折茂 達也, 長津 明久, 相山 健, 蒲池 浩文, 武冨 紹信
    日本外科学会定期学術集会抄録集, 122回, SF, 5, (一社)日本外科学会, 2022年04月
    日本語
  • Laparoscopic liver resection for liver metastasis of leiomyosarcoma of the thigh: a case report.
    Shoichi Tsuzaka, Yoh Asahi, Toshiya Kamiyama, Tatsuhiko Kakisaka, Tatsuya Orimo, Akihisa Nagatsu, Takeshi Aiyama, Takeyuki Uebayashi, Hirofumi Kamachi, Masatake Matsuoka, Kento Wakabayashi, Takuya Otsuka, Yoshihiro Matsuno, Akinobu Taketomi
    Surgical case reports, 8, 1, 47, 47, 2022年03月21日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Although there is no established treatment strategy for liver metastasis of leiomyosarcoma, liver resection has been reported to be effective in some cases. However, almost all liver resections performed for liver metastasis of primary leiomyosarcoma are reported to be open resections, and there are few reports of liver resection performed by laparoscopy. Here, we report a case of laparoscopic liver resection for liver metastasis of a leiomyosarcoma in the right thigh. CASE PRESENTATION: An 80-year-old man was diagnosed with leiomyosarcoma of the right thigh with liver metastasis. The primary tumor was first resected, and he was discharged on the 25th postoperative day. Four months after primary tumor resection, a laparoscopic right posterior sectionectomy was performed. There were no postoperative complications, and the patient was discharged on the 11th postoperative day with a histopathological diagnosis of liver metastasis of leiomyosarcoma and negative resection margins. Currently, 9 months have passed since the resection of the primary tumor, and 5 months have passed since the laparoscopic liver resection; there is no recurrence. CONCLUSIONS: The liver metastasis of leiomyosarcoma was successfully removed, with good short-term outcomes after the laparoscopic liver resection. Laparoscopic liver resection seems to be effective for liver metastasis of leiomyosarcoma, which is characterized by a high recurrence rate after surgery. However, more case studies may be necessary to examine the effectiveness and long-term results of laparoscopic liver resection for the treatment of liver metastasis of leiomyosarcoma.
  • 肝細胞癌患者の治癒切除後長期予後における腎機能障害の影響               
    坂本 譲, 神山 俊哉, 島田 慎吾, 相山 健, 旭 よう, 長津 明久, 折茂 達也, 柿坂 達彦, 蒲池 浩文, 武冨 紹信
    日本臨床外科学会雑誌, 83, 3, 598, 599, 日本臨床外科学会, 2022年03月
    日本語
  • Preventing Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy With Active Hexose-correlated Compound Derived From Lentinula edodes Mycelia.
    Toshiya Kamiyama, Tatsuya Orimo, Kenji Wakayama, Tatsuhiko Kakisaka, Shingo Shimada, Akihisa Nagatsu, Yoh Asahi, Takeshi Aiyama, Hirofumi Kamachi, Akinobu Taketomi
    Integrative cancer therapies, 21, 15347354211073066, 15347354211073066, 2022年, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: Active hexose-correlated compound (AHCC), a standardized extract of cultured Lentinula edodes mycelia, exerts antitumor effects through anti-inflammatory and immune-modulatory functions. Adjuvant therapy for patients with hepatocellular carcinoma (HCC) who have undergone curative hepatectomy has not been established. The purpose of this study was to evaluate the efficacy and safety of AHCC as adjuvant therapy in patients with advanced HCC after curative hepatectomy. PATIENTS AND METHODS: The study design was single-armed, non-randomized, open (no one was blinded), and uncontrolled. Patients with HCC who underwent curative hepatectomy were treated with AHCC (1 g) 3 times daily orally for 2 years. The inclusion criteria were HCC diagnosed preoperatively as stages A and B of the Barcelona clinic liver cancer (BCLC) classification and alpha-fetoprotein × protein induced by vitamin K absence or antagonist II (PIVKA-II) ≥ 105 for stage A. RESULTS: A total of 29 patients were treated with AHCC, of which 25 (4 patients discontinued) were followed up. The 2-year recurrence-free survival rate after resection was 48% for those without discontinuations and 55.2% for all patients with a history of treatment. Serum albumin levels decreased to a minimum in the first postoperative month and gradually recovered to the preoperative level at 6 months. Almost no change in lymphocyte percentage was observed during follow-up. Inflammation-based prognostic scores were maintained at favorable levels after hepatectomy. Toxicity and adverse events were not observed in any patient. CONCLUSION: AHCC may be safe and effective in preventing HCC recurrence after curative hepatectomy, and further randomized trials of AHCC for its use in this setting are warranted.This clinical trial was registered in UMIN Clinical Trials Registry (ID UMIN000024396).
  • 早期肝細胞癌に対する腹腔鏡下肝部分切除術の治療成績               
    旭 よう, 神山 俊哉, 柿坂 達彦, 折茂 達也, 長津 明久, 相山 健, 蒲池 浩文, 武冨 紹信
    日本内視鏡外科学会雑誌, 26, 7, MO084, 6, (一社)日本内視鏡外科学会, 2021年12月
    日本語
  • Outcomes of reduction hepatectomy combined with postoperative multidisciplinary therapy for advanced hepatocellular carcinoma.
    Yoh Asahi, Toshiya Kamiyama, Tatsuhiko Kakisaka, Tatsuya Orimo, Shingo Shimada, Akihisa Nagatsu, Takeshi Aiyama, Yuzuru Sakamoto, Hirofumi Kamachi, Akinobu Taketomi
    World journal of gastrointestinal surgery, 13, 10, 1245, 1257, 2021年10月27日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The prognosis of advanced hepatocellular carcinoma (HCC) that is not indicated for curative hepatectomy remains poor, despite advances in the treatment of HCC, including the development of tyrosine kinase inhibitors (TKIs). The outcomes of reduction hepatectomy and multidisciplinary postoperative treatment for advanced HCC that is not indicated for curative hepatectomy, including those of recently treated cases, should be investigated. AIM: To examine the outcomes of combination treatment with reduction hepatectomy and multidisciplinary postoperative treatment for advanced HCC that is not indicated for curative hepatectomy. METHODS: Thirty cases of advanced HCC that were not indicated for curative hepatectomy, in which reduction hepatectomy was performed between 2000 and 2018 at the Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, were divided into postoperative complete remission (POCR) (+) and POCR (-) groups, depending on whether POCR of all evaluable lesions was achieved through postoperative treatment. The cases in the POCR (-) group were subdivided into POCR (-) TKI (+) and POCR (-) TKI (-) groups, depending on whether TKIs were administered postoperatively. RESULTS: The 5-year overall survival rate and mean survival time (MST) after reduction hepatectomy were 15.7% and 28.40 mo, respectively, for all cases; 37.5% and 56.55 mo, respectively, in the POCR (+) group; and 6.3% and 14.84 mo, respectively, in the POCR (-) group (P = 0.0041). Tumor size, major vascular invasion, and the number of tumors in the remnant liver after the reduction hepatectomy were also found to be related to survival outcomes. The number of tumors in the remnant liver was the only factor that differed significantly between the POCR (+) and POCR (-) groups, and POCR was achieved significantly more frequently when ≤ 3 tumors remained in the remnant liver (P = 0.0025). The MST was 33.52 mo in the POCR (-) TKI (+) group, which was superior to the MST of 10.74 mo seen in the POCR (-) TKI (-) group (P = 0.0473). CONCLUSION: Reduction hepatectomy combined with multidisciplinary postoperative treatment for unresectable advanced HCC that was not indicated for curative hepatectomy was effective when POCR was achieved via multidisciplinary postoperative therapy. To achieve POCR, reduction hepatectomy should aim to ensure that ≤ 3 tumors remain in the remnant liver. Even in cases in which POCR is not achieved, combined treatment with reduction hepatectomy and multidisciplinary therapy can improve survival outcomes when TKIs are administered.
  • PTPE後に中等症COVID-19を罹患したが、呼吸状態改善後に治癒的切除をし得た転移性肝腫瘍の1例               
    藤好 直, 柿坂 達彦, 下國 達志, 松澤 文彦, 木井 修平, 蔵谷 勇樹, 西川 眞, 高橋 昌弘
    日本臨床外科学会雑誌, 82, 増刊, S765, S765, 日本臨床外科学会, 2021年10月
    日本語
  • 肝細胞癌に対する最新の集学的治療 術後再発肝細胞癌に対する分子標的薬使用の意義               
    旭 よう, 神山 俊哉, 折茂 達也, 柿坂 達彦, 長津 明久, 相山 健, 蒲池 浩文, 武冨 紹信
    日本臨床外科学会雑誌, 82, 増刊, S280, S280, 日本臨床外科学会, 2021年10月
    日本語
  • Combined treatment of an aortosplenic bypass followed by coil embolization in the treatment of pancreaticoduodenal artery aneurysms caused by median arcuate ligament compression: a report of two cases.
    Shuhei Kii, Hirofumi Kamachi, Daisuke Abo, Takuya Kato, Yousuke Tsuruga, Kenji Wakayama, Tatsuhiko Kakisaka, Takeshi Soyama, Toshiya Kamiyama, Tomonori Ooka, Satoru Wakasa, Akinobu Taketomi
    Surgical case reports, 7, 1, 174, 174, 2021年08月04日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Pancreaticoduodenal artery aneurysms (PDAAs) are rare visceral aneurysms, and prompt intervention/treatment of all PDAAs is recommended at the time of diagnosis to avoid rupture of aneurysms. Herein, we report two cases of PDAA caused by the median arcuate ligament syndrome, treated with surgical revascularization by aortosplenic bypass followed by coil embolization. CASE PRESENTATION: Case 1 A 54-year-old woman presented with a chief complaint of severe epigastralgia and was diagnosed with two large fusiform inferior PDAAs and celiac axis occlusion. To preserve the blood flow of the pancreatic head, duodenum, liver, and spleen, we performed elective surgery to release the MAL along with aortosplenic bypass. At 6 days postoperatively, transcatheter arterial embolization was performed. At the 8-year 6-month follow-up observation, no recurrent perfusion of the embolized PDAAs or rupture had occurred, including the non-embolized small PDAA, and the bypass graft had excellent patency. Case 2 A 39-year-old man who had been in good health was found to have a PDAA with celiac stenosis during a medical checkup. Computed tomography and superior mesenteric arteriography showed severe celiac axis stenosis and a markedly dilated pancreatic arcade with a large saccular PDAA. To preserve the blood flow of the pancreatic arcade, we performed elective surgery to release the MAL along with aortosplenic bypass. At 9 days postoperatively, transcatheter arterial embolization was performed. At the 6-year 7-month follow-up observation, no recurrent perfusion or rupture of the PDAA had occurred, and the bypass graft had excellent patency. CONCLUSION: Combined treatment with bypass surgery and coil embolization can be an effective option for the treatment of PDAAs associated with celiac axis occlusion or severe stenosis.
  • 高齢者に対する肝臓外科治療 後期高齢者における術前経皮経肝的門脈塞栓術の有用性の検討               
    坂本 譲, 神山 俊哉, 島田 慎吾, 旭 よう, 長津 明久, 折茂 達也, 柿坂 達彦, 蒲池 浩文, 武冨 紹信
    日本消化器外科学会総会, 76回, PD5, 7, (一社)日本消化器外科学会, 2021年07月
    日本語
  • BRA膵癌に対する治療戦略 BR膵癌に対するジェムシタビン併用術前化学放射線療法の成績               
    蒲池 浩文, 折茂 達也, 柿坂 達彦, 島田 慎吾, 長津 明久, 旭 よう, 坂本 譲, 神山 俊哉, 武冨 紹信
    日本消化器外科学会総会, 76回, O34, 6, (一社)日本消化器外科学会, 2021年07月
    日本語
  • 非大腸癌肝転移に対する肝切除の意義 悪性黒色腫肝転移に対する肝切除と免疫チェックポイント阻害剤の使用 3症例の検討               
    旭 よう, 神山 俊哉, 柿坂 達彦, 折茂 達也, 長津 明久, 坂本 譲, 蒲池 浩文, 武冨 紹信
    日本消化器外科学会総会, 76回, RS18, 3, (一社)日本消化器外科学会, 2021年07月
    日本語
  • Comparison of laparoscopic and open hepatectomy with synchronous colectomy for colorectal cancer with synchronous liver metastasis(和訳中)               
    Asahi Yoh, Kamiyama Toshiya, Kakisaka Tatsuhiko, Orimo Tatsuya, Nagatsu Akihisa, Sakamoto Yuzuru, Kamachi Hirofumi, Homma Shigenori, Ichikawa Nobuki, Yoshida Tadashi, Taketomi Akinobu
    日本肝胆膵外科学会・学術集会プログラム・抄録集, 33回, 291, 291, (一社)日本肝胆膵外科学会, 2021年06月
    英語
  • A case of laparoscopic hepatectomy for a primary hepatic neuroendocrine tumor.
    Yuzuru Sakamoto, Shingo Shimada, Toshiya Kamiyama, Tatsuya Orimo, Akihisa Nagatsu, Yoh Asahi, Tatsuhiko Kakisaka, Hirofumi Kamachi, Tomoko Mitsuhashi, Akinobu Taketomi
    Clinical journal of gastroenterology, 14, 3, 876, 880, 2021年06月, [国内誌]
    英語, 研究論文(学術雑誌), Neuroendocrine tumors (NETs) account for approximately 1-2% of all gastrointestinal tumors. In particular, primary hepatic NETs (PHNETs) are extremely rare. A 42-year-old female patient was given a diagnosis of liver tumor after a medical check-up with ultrasonography. An enhanced CT scan and MRI were suggestive for a hepatic hemangioma or adenoma, but the possibility of hepatocellular carcinoma could not be denied. Moreover, this tumor grew larger, so we performed a laparoscopic partial hepatectomy for the diagnosis and treatment of the patient. Pathological examination revealed that the tumor cells were spindle-shaped, forming glandular-tubular structures, and had less visible nucleoli and increased mitotic figures on H&E staining. Immunohistochemical findings indicated that CK19, MOC-31, CD56, synaptophysin, and chromogranin A were positive; CK7, AFP, and glypican-3 were negative; and the Ki-67 index was 3.6%, so the final diagnosis was a PHNET G2. PHNETs differ from other NETs, as they do not produce biologically active polypeptides or amines. As a result, there are no manifestations of carcinoid syndrome. In addition, PHNETs grow slowly, and most patients show no symptoms in the early stages. Laparoscopic hepatectomy is a very useful procedure for diagnosis and treatment in such cases and can be performed safely.
  • The impact of elastography with virtual touch quantification of future remnant liver before major hepatectomy.
    Shingo Shimada, Toshiya Kamiyama, Tatsuhiko Kakisaka, Tatsuya Orimo, Akihisa Nagatsu, Yoh Asahi, Yuzuru Sakamoto, Hirofumi Kamachi, Yusuke Kudo, Mutsumi Nishida, Akinobu Taketomi
    Quantitative imaging in medicine and surgery, 11, 6, 2572, 2585, 2021年06月, [国際誌]
    英語, 研究論文(学術雑誌), Background: Liver elastography with virtual touch quantification (VTQ) measures the velocity of the shear wave generated by a short-duration acoustic force impulse, with values expressed in units of velocity (m/s). VTQ can evaluate right or left hepatic lobes separately. VTQ might be appropriate for the evaluation of future remnant liver after hepatectomy. Methods: We analyzed 95 patients underwent liver elastography with VTQ and both future remnant liver and resected side before hepatectomy of more than two sections, except for central bisectionectomy. We divided the patients into a high VTQ group (≥1.52 m/s, n=37, 39%) and a low VTQ group (<1.52 m/s, n=58, 61%) according to the VTQ of future remnant liver. Transient elastography could not be performed in 22 cases due to tumor size. We defined the group with liver stiffness measurement (LSM) ≥7.9 kPa as the high LSM group (n=29, 40%) and those with LSM <7.9 kPa as the low LSM group (n=44, 60%). We investigated the outcome after hepatectomy and the correlations between the VTQ of future remnant liver and other indicators for hepatic fibrosis. Results: The high VTQ group showed significantly higher postoperative ascites (19% vs. 3%; P=0.01), pathological fibrosis (19% vs. 5%; P=0.03), and rates of patients with postoperative T-bil ≥2.0 mg/dL (70% vs. 40%; P<0.01). The high LSM group showed no significant postoperative outcomes compared to the low LSM group. The high VTQ group showed a higher frequency of male gender (78% vs. 57%; P=0.03), higher indocyanine green retention rate at 15 min (ICGR15) (10.5% vs. 6.3%; P<0.01), hyaluronic acid (100 vs. 67 ng/mL; P=0.02), type IV collagen 7S (7.6 vs. 5.1 ng/mL; P<0.01), Mac-2 binding protein glycan isomer (M2BPGi) (1.19 vs. 1.00; P=0.01), Fibrosis-4 (FIB-4) index (2.25 vs. 1.76; P=0.01), and aspartate aminotransferase to platelet ratio index (APRI) score (0.64 vs. 0.41; P<0.01). We also observed an especially strong positive correlation between the high VTQ and hyaluronic acid or type IV collagen 7S. Conclusions: Elastography with VTQ for future remnant liver before major hepatectomy is an accurate and useful method as a preoperative evaluation.
  • Genomewide transcriptomic profiling identifies a gene signature for predicting recurrence in early-stage hepatocellular carcinoma.
    Tatsuhiko Kakisaka, Moto Fukai, Jasjit K Banwait, Toshiya Kamiyama, Tatsuya Orimo, Tomoko Mitsuhashi, Kensuke Yamamura, Takeo Toshima, Hideo Baba, Akinobu Taketomi, Ajay Goel
    Clinical and translational medicine, 11, 6, e405, 2021年06月, [国際誌]
    英語
  • Treatment Outcomes of Stereotactic Body Radiation Therapy Using Real-time Tumor-tracking Radiotherapy System for Hepatocellular Carcinomas.
    Yusuke Uchinami, Norio Katoh, Daisuke Abo, Hiroshi Taguchi, Koichi Yasuda, Kentaro Nishioka, Takeshi Soyama, Ryo Morita, Naoki Miyamoto, Ryusuke Suzuki, Takuya Sho, Masato Nakai, Koji Ogawa, Tatsuhiko Kakisaka, Tatsuya Orimo, Toshiya Kamiyama, Shinichi Shimizu, Hidefumi Aoyama
    Hepatology research : the official journal of the Japan Society of Hepatology, 51, 8, 870, 879, 2021年04月24日, [国際誌]
    英語, 研究論文(学術雑誌), AIM: To report the outcomes of stereotactic body radiotherapy (SBRT) using a real-time tumor-tracking radiotherapy (RTRT) system for hepatocellular carcinoma (HCC) patients. METHODS: From January 2005 to July 2018, 63 patients with 74 lesions with a maximum diameter ≤52 mm were treated by SBRT using the RTRT system. No patient with a Child-Pugh Score ≥9 was included and 85.6% had a score of 5 or 6. Using the biological effective dose (BED) with α/β ratio of 10 (BED10 ), the median dose in BED10 at the reference point was 76.8 Gy (range: 60-122.5). Overall survival (OS) and local control (LC) rates were assessed using the Kaplan-Meier method. RESULTS: With a median follow up period of 24.6 months (range: 0.9-118.4), the 1-year and 2-year OS rates were 86.8% (95% confidence interval [95% CI]; 75.8-93.3) and 71.1% (57.8-81.6), respectively. The 2-year OS was 89.6% in patients with the baseline modified albumin-bilirubin (mALBI) grade =1 and 61.7% in patients with grade ≥2a. In the multivariate analysis, the mALBI grade (=1 vs ≥2a) was a significant factor for OS (p=0.028, 95%CI: 1.11-6.18). The 1-year and 2-year LC rates were 100% (100-100) and 92.0% (77.5-97.5). The LC rates were significantly higher in the BED10 ≥100 Gy group than in the BED10 <100 Gy (2-year 100% vs 86.5%, p=0.049) at the reference point. CONCLUSION: This retrospective study of SBRT using RTRT for HCC showed favorable outcomes with lower incidence of toxicities, especially in patients treated with BED10 ≥100 Gy to the reference point. This article is protected by copyright. All rights reserved.
  • 肥満合併肝細胞癌患者における肝切除の検討               
    坂本 譲, 神山 俊哉, 島田 慎吾, 折茂 達也, 長津 明久, 旭 よう, 柿坂 達彦, 蒲池 浩文, 武冨 紹信
    日本外科学会定期学術集会抄録集, 121回, PS, 8, (一社)日本外科学会, 2021年04月
    日本語
  • 肝前区域切除術後に胆管狭窄に伴う肝後区域の萎縮を呈した2例               
    石川 倫啓, 柿坂 達彦, 坂本 譲, 旭 よう, 長津 明久, 島田 慎吾, 折茂 達也, 蒲池 浩文, 神山 俊哉, 武冨 紹信
    日本外科学会定期学術集会抄録集, 121回, PS, 8, (一社)日本外科学会, 2021年04月
    日本語
  • MicroRNAs in Colon Tissue of Pediatric Ulcerative Pancolitis Patients Allow Detection and Prognostic Stratification.
    Petr Jabandziev, Tatsuhiko Kakisaka, Julia Bohosova, Tereza Pinkasova, Lumir Kunovsky, Ondrej Slaby, Ajay Goel
    Journal of clinical medicine, 10, 6, 2021年03月23日, [国際誌]
    英語, 研究論文(学術雑誌), Prevalence of inflammatory bowel disease has been on the rise in recent years, especially in pediatric populations. This study aimed to provide precise identification and stratification of pediatric patients with diagnosed ulcerative colitis (UC) according to the severity of their condition and the prediction for standard treatment according to the specific expression of candidate miRNAs. We enrolled consecutive, therapeutically naïve, pediatric UC patients with confirmed pancolitis. We examined formalin-fixed paraffin-embedded specimens of colonic tissue for the expression of 10 selected candidate miRNAs. We performed receiver operating characteristic curve analysis, using area under the curve and a logistic regression model to evaluate the diagnostic and predictive power of the miRNA panels. Sixty patients were included in the final analysis. As a control group, 18 children without macroscopic and microscopic signs of inflammatory bowel disease were examined. The combination of three candidate miRNAs (let-7i-5p, miR-223-3p and miR-4284) enabled accurate detection of pediatric UC patients and controls. A panel of four candidate miRNAs (miR-375-3p, miR-146a-5p, miR-223-3p and miR-200b-3p) was associated with severity of UC in pediatric patients and a combination of three miRNAs (miR-21-5p, miR-192-5p and miR-194-5p) was associated with early relapse of the disease. Nine patients out of the total were diagnosed with primary sclerosing cholangitis (PSC) simultaneously with ulcerative colitis. A panel of 6 candidate miRNAs (miR-142-3p, miR-146a-5p, miR-223-3p, let-7i-5p, miR-192-5p and miR-194-5p) identified those patients with PSC. Specific combinations of miRNAs are promising tools for potential use in precise disease identification and severity and prognostic stratification in pediatric patients with ulcerative pancolitis.
  • 悪性黒色腫の肝転移に対して肝切除を行った4症例の報告               
    旭 よう, 神山 俊哉, 柿坂 達彦, 折茂 達也, 長津 明久, 坂本 譲, 蒲池 浩文, 竹内 啓, 三橋 智子, 武冨 紹信
    日本消化器病学会雑誌, 118, 臨増総会, A390, A390, (一財)日本消化器病学会, 2021年03月
    日本語
  • Central Hepatectomy Versus Major Hepatectomy for Centrally Located Hepatocellular Carcinoma: A Propensity Score Matching Study.
    Tatsuya Orimo, Toshiya Kamiyama, Tatsuhiko Kakisaka, Shingo Shimada, Akihisa Nagatsu, Yoh Asahi, Yuzuru Sakamoto, Hirofumi Kamachi, Akinobu Taketomi
    Annals of surgical oncology, 28, 11, 6769, 6779, 2021年03月01日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: In terms of anatomical liver sectionectomy approaches, both a central hepatectomy (CH) and major hepatectomy (MH) are feasible options for a centrally located hepatocellular carcinoma (HCC). METHODS: We retrospectively reviewed the surgical outcomes of central HCC patients who underwent CH or MH. MH includes hemihepatectomy or trisectionectomy, whereas CH involves a left medial sectionectomy, right anterior sectionectomy, or central bisectionectomy. The surgical outcomes were compared before and after propensity score matching (PSM). RESULTS: A total of 233 patients were enrolled, including 132 in the CH group and 101 in the MH group. The MH group cases were pathologically more advanced and had poorer overall survival rates than the CH group. After PSM, 68 patients were selected into each group, both of which showed similar overall and recurrence-free survival outcomes. The CH group showed a tendency for a longer operation time; however, other perioperative outcomes were similar between the two groups. Multivariate analyses of our matched HCC patients revealed that the type of surgery (CH or MH) was not an independent prognostic factor. More patients in the matched CH group experienced a repeat hepatectomy for recurrence and no patients in this group underwent a preoperative portal vein embolization. CONCLUSIONS: The short- and long-term surgical outcomes of CH and MH for a centrally located HCC are similar under a matched clinicopathological background. CH has the advantage of not requiring a preoperative portal vein embolization and increased chances of conducting a repeat hepatectomy for recurrence.
  • Functional transition: Inconsistently parallel to the increase in future liver remnant volume after preoperative portal vein embolization.
    Yosuke Tsuruga, Toshiya Kamiyama, Hirofumi Kamachi, Tatsuya Orimo, Shingo Shimada, Akihisa Nagatsu, Yoh Asahi, Yuzuru Sakamoto, Tatsuhiko Kakisaka, Akinobu Taketomi
    World journal of gastrointestinal surgery, 13, 2, 153, 163, 2021年02月27日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Preoperative portal vein embolization (PVE) is a widely used strategy to enable major hepatectomy in patients with insufficient liver remnant. PVE induces hypertrophy of the future liver remnant (FLR) and a shift of the functional reserve to the FLR. However, whether the increase of the FLR volume (FLRV) corresponds to the functional transition after PVE remains unclear. AIM: To investigate the sequential relationship between the increase in FLRV and functional transition after preoperative PVE using 3-dimensional (3D) computed tomography (CT) and 99mTc-galactosyl-human serum albumin (99mTc-GSA) single-photon emission computed tomography (SPECT) fusion images. METHODS: Thirty-three patients who underwent major hepatectomy following PVE at the Department of Gastroenterological Surgery I, Hokkaido University Hospital between October 2013 and March 2018 were enrolled. Three-phase dynamic multidetector CT and 99mTc-GSA SPECT scintigraphy were performed at pre-PVE, and at 1 and 2 wk after PVE; 3D 99mTc-GSA SPECT CT-fused images were constructed from the Digital Imaging and Communications in Medicine data using 3D image analysis system. Functional FLRV (FFLRV) was defined as the total liver volume × (FLR volume counts/total liver volume counts) on the 3D 99mTc-GSA SPECT CT-fused images. The calculated FFLRV was compared with FLRV. RESULTS: FFLRV increased by a significantly larger extent than FLRV at 1 and 2 wk after PVE (P < 0.01). The increase in FFLRV and FLRV was 55.1% ± 41.6% and 26.7% ± 17.8% (P < 0.001), respectively, at 1 wk after PVE, and 64.2% ± 33.3% and 36.8% ± 18.9% (P < 0.001), respectively, at 2 wk after PVE. In 3 of the 33 patients, FFLRV levels decreased below FLRV at 2 wk. One of the three patients showed rapidly progressive fatty changes in FLR. The biopsy at 4 wk after PVE showed macro- and micro-vesicular steatosis of more than 40%, which improved to 10%. Radical resection was performed at 13 wk after PVE. The patient recovered uneventfully without any symptoms of pos-toperative liver failure. CONCLUSION: The functional transition lagged behind the increase in FLRV after PVE in some cases. Evaluating both volume and function is needed to determine the optimal timing of hepatectomy after PVE.
  • Current role of intraoperative ultrasonography in hepatectomy.
    Toshiya Kamiyama, Tatsuhiko Kakisaka, Tatsuya Orimo
    Surgery today, 2021年01月04日, [国内誌]
    英語, 研究論文(学術雑誌), Hepatectomy had a high mortality rate in the previous decade because of inadequate techniques, intraoperative blood loss, liver function reserve misdiagnoses, and accompanying postoperative complications. However, the development of several modalities, including intraoperative ultrasonography (IOUS), has made hepatectomy safer. IOUS can provide real-time information regarding the tumor position and vascular anatomy of the portal and hepatic veins. Systematic subsegmentectomy, which leads to improved patient outcomes, can be performed by IOUS in open and laparoscopic hepatectomy. Although three-dimensional (3D) computed tomography and gadoxetic acid-enhanced magnetic resonance imaging have been widely used, IOUS and contrast-enhanced IOUS are important modalities for risk analyses and making decisions regarding resectability and operative procedures because of the vital anatomical information provided and high sensitivity for liver tumors, including "disappearing" liver metastases. Intraoperative color Doppler ultrasonography can be used to delineate the vascular anatomy and evaluate the blood flow volume and velocity in hepatectomy patients and recipients of deceased- and living-donor liver transplantation after vessel reconstruction and liver positioning. For liver surgeons, IOUS is an essential technique to perform highly curative hepatectomy safely, although recent advances have also been made in virtual modalities, such as real-time virtual sonography with 3D visualization.
  • Impact of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging on the prognosis of hepatocellular carcinoma after surgery.
    Shingo Shimada, Toshiya Kamiyama, Tatsuhiko Kakisaka, Tatsuya Orimo, Akihisa Nagatsu, Yoh Asahi, Yuzuru Sakamoto, Daisuke Abo, Hirofumi Kamachi, Akinobu Taketomi
    JGH open : an open access journal of gastroenterology and hepatology, 5, 1, 41, 49, 2021年01月, [国際誌]
    英語, 研究論文(学術雑誌), Background and Aim: Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (EOB-MRI) has been recognized as a useful imaging technique to distinguish the biological behavior of hepatocellular carcinoma (HCC). Methods: We analyzed 217 hepatectomy recipients with HCCs measuring 10 cm or less. We divided the patients into a decreased intensity (DI) group (n = 189, 87%) and an increased or neutral intensity (INI) group (n = 28, 13%) according to the ratio of tumor intensity to liver intensity during the hepatobiliary phase (HBP). According to the ratio of the maximum tumor diameter (including peritumoral hypointensity) between HBP images and precontrast T1-weighted images (RHBPP), we divided the patients as follows: The group whose RHBPP was ≥1.036 was the high RHBPP group (n = 60, 28%), and the group whose RHBPP was <1.036 was the low RHBPP group (n = 157, 72%). We investigated the prognoses and clinicopathological characteristics of these patients. Results: DI versus INI was not a prognostic factor for either survival or recurrence; however, a high RHBPP was an independent predictor of unfavorable survival and recurrence in patients. In addition, the INI group showed significantly lower α-fetoprotein (AFP) levels and higher rates of well-differentiated HCC and ICGR15 ≥15% than the DI group. The high RHBPP group showed significantly higher rates of vascular invasion and poorly differentiated HCC than the low RHBPP group. Conclusions: A high RHBPP by EOB-MRI is a preoperative predictor of vascular invasion and an unfavorable prognostic factor for survival and recurrence. These patients might be considered for highly curative operations such as anatomical liver resection.
  • Analysis of the correlation between alterations in N‑glycans and invasiveness in liver cancer cell lines.
    Hidenori Takahashi, Toshiya Kamiyama, Nozomi Hirane, Nozomi Kobayashi, Takeshi Aiyama, Akihisa Nagatsu, Shingo Shimada, Tatsuya Orimo, Tatsuhiko Kakisaka, Moto Fukai, Hideki Yokoo, Hirofumi Kamachi, Shin-Ichiro Nishimura, Akinobu Taketomi
    Oncology reports, 44, 6, 2757, 2769, 2020年12月, [国際誌]
    英語, 研究論文(学術雑誌), The N‑glycoforms of glycoproteins modify protein function and control a number of biological pathways. The aim of the present study was to investigate the correlation between alterations in N‑glycans and cancer aggressiveness in terms of cancer cell invasion ability. The expression of urokinase‑type plasminogen activator (uPA) and N‑acetylglucosaminyltransferase V (GnT‑V) in liver cancer cell lines was analyzed by western blotting. Cell invasiveness was analyzed by Matrigel invasion assays. uPA and GnT‑V expression in liver cancer cell lines was knocked down by RNA interference. Furthermore, uPA was overexpressed in liver cancer cells using lentiviral vectors, and a mutant strain of HepG2 cells overexpressing uPA deficient in N‑glycans was established. A glycoblotting‑assisted matrix‑assisted laser desorption/ionization‑time‑of‑flight/mass spectrometry‑based quantitative analysis of liver cancer cell lines was performed, in which invasiveness was altered by modifying the expression of uPA and GnT‑V. N‑glycan profiles were found to differ between the highly invasive liver cancer cell line HLE and the less invasive cell line HepG2. The expression of several N‑glycans, including a form with m/z=1892, was changed according to invasiveness controlled by knockdown and overexpression of uPA. The invasiveness of HepG2 cells with mutant uPA did not increase regardless of the level of expression of uPA. Following GnT‑V knockdown and N‑glycan alteration, uPA expression did not change, whereas cell invasiveness decreased. One N‑glycan (m/z=1892) was common among N‑glycans in the comparative analysis between HLE and HepG2, HLE and uPA knockdown HLE, HepG2 and uPA‑overexpressing HepG2, and HLE and GnT‑V knockdown HLE cells and among N‑glycan profiles in human uPA. Therefore, N‑glycosylation is an important factor controlling invasiveness of liver cancer cells, and a specific N‑glycan (m/z=1892) associated with the invasion of liver cancer cells via uPA was identified in the present study.
  • Xenograftマウスモデルを用いた抗メソテリン抗体の早期投与による膵癌肝転移抑制効果の検討               
    藤居 勇貴, 蒲池 浩文, 深井 原, 折茂 達也, 坂本 譲, 旭 よう, 長津 明久, 島田 慎吾, 柿坂 達彦, 神山 俊哉, 武冨 紹信
    日本癌学会総会記事, 79回, OJ14, 4, (一社)日本癌学会, 2020年10月
    英語
  • 肝切除を施行後集学的治療にて長期生存が得られているG-CSF産生肝細胞癌の1例               
    坂本 譲, 神山 俊哉, 旭 よう, 長津 明久, 島田 慎吾, 折茂 達也, 柿坂 達彦, 蒲池 浩文, 武冨 紹信
    日本癌治療学会学術集会抄録集, 58回, P, 190, (一社)日本癌治療学会, 2020年10月
    日本語
  • CD133 and epithelial cell adhesion molecule expressions in the cholangiocarcinoma component are prognostic factors for combined hepatocellular cholangiocarcinoma.
    Kazuki Wakizaka, Hideki Yokoo, Toshiya Kamiyama, Tatsuhiko Kakisaka, Masafumi Ohira, Michio Tani, Koichi Kato, Yuki Fujii, Ko Sugiyama, Akihisa Nagatsu, Shingo Shimada, Tatsuya Orimo, Hirofumi Kamachi, Ryosuke Matsuoka, Akinobu Taketomi
    Hepatology research : the official journal of the Japan Society of Hepatology, 50, 2, 258, 267, 2020年02月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), AIM: A new classification of combined hepatocellular cholangiocarcinoma (CHC) was recently reported. Cancer stem cells have been associated with CHC carcinogenesis. This study examined the association of cancer stem cell marker expression and prognosis in CHC classified using the new classification. METHODS: We enrolled 26 CHC patients and classified them according to the new classification. We evaluated the expression of cancer stem cell markers (CD56, CD133, and epithelial cell adhesion molecule [EpCAM]) by immunohistochemical staining in each component. We analyzed the association between expressions and prognosis. RESULTS: Seven cases were hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) (cHCC-CCA), 12 were HCC and intermediate cell carcinoma (HCC-INT), and seven were intermediate cell carcinoma (INT). The CD133-positive rate tended to be higher in the CCA (42.9%) and INT component (50.0%) than the HCC component (14.3%) in cHCC-CCA. In HCC-INT, the CD133-positive rate in the INT component (83.3%) was significantly higher than the HCC component (8.3%; P = 0.001). For EpCAM, the positive rate in the CCA component (71.4%) and INT component (50.0%) tended to be higher than the HCC component (14.3%) in cHCC-CCA. Overall survival and disease-free survival were significantly worse in cases with CD133-positive (P = 0.048 and P = 0.048, respectively) or EpCAM-positive (P = 0.041 and P = 0.041, respectively) CCA component in cHCC-CCA. CONCLUSIONS: INT and CCA components showed higher expression rates of cancer stem cell markers than the HCC component. CD133 or EpCAM expression in the CCA component was associated with poor prognosis in cHCC-CCA.
  • Uncovering Potential Therapeutic Targets in Colorectal Cancer by Deciphering Mutational Status and Expression of Druggable Oncogenes.
    Otília Menyhart, Tatsuhiko Kakisaka, Lőrinc Sándor Pongor, Hiroyuki Uetake, Ajay Goel, Balázs Győrffy
    Cancers, 11, 7, 2019年07月14日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Numerous driver mutations have been identified in colorectal cancer (CRC), but their relevance to the development of targeted therapies remains elusive. The secondary effects of pathogenic driver mutations on downstream signaling pathways offer a potential approach for the identification of therapeutic targets. We aimed to identify differentially expressed genes as potential drug targets linked to driver mutations. METHODS: Somatic mutations and the gene expression data of 582 CRC patients were utilized, incorporating the mutational status of 39,916 and the expression levels of 20,500 genes. To uncover candidate targets, the expression levels of various genes in wild-type and mutant cases for the most frequent disruptive mutations were compared with a Mann-Whitney test. A survival analysis was performed in 2100 patients with transcriptomic gene expression data. Up-regulated genes associated with worse survival were filtered for potentially actionable targets. The most significant hits were validated in an independent set of 171 CRC patients. RESULTS: Altogether, 426 disruptive mutation-associated upregulated genes were identified. Among these, 95 were linked to worse recurrence-free survival (RFS). Based on the druggability filter, 37 potentially actionable targets were revealed. We selected seven genes and validated their expression in 171 patient specimens. The best independently validated combinations were DUSP4 (p = 2.6 × 10-12) in ACVR2A mutated (7.7%) patients; BMP4 (p = 1.6 × 10-04) in SOX9 mutated (8.1%) patients; TRIB2 (p = 1.35 × 10-14) in ACVR2A mutated patients; VSIG4 (p = 2.6 × 10-05) in ANK3 mutated (7.6%) patients, and DUSP4 (p = 7.1 × 10-04) in AMER1 mutated (8.2%) patients. CONCLUSIONS: The results uncovered potentially druggable genes in colorectal cancer. The identified mutations could enable future patient stratification for targeted therapy.
  • Hepatic hypertrophy and hemodynamics of portal venous flow after percutaneous transhepatic portal embolization.
    Shingo Shimada, Toshiya Kamiyama, Hideki Yokoo, Tatsuya Orimo, Kenji Wakayama, Akihisa Nagatsu, Tatsuhiko Kakisaka, Hirofumi Kamachi, Daisuke Abo, Yusuke Sakuhara, Akinobu Taketomi
    BMC surgery, 19, 1, 23, 23, 2019年02月18日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Percutaneous transhepatic portal embolization (PTPE) is useful for safe major hepatectomy. This study investigated the correlation between hepatic hypertrophy and hemodynamics of portal venous flow by ultrasound sonography after PTPE. METHODS: We analyzed 58 patients with PTPE, excluding those who underwent recanalization (n = 10). Using CT volumetry results 2 weeks after PTPE, the patients were stratified into a considerable hypertrophy group (CH; n = 15) with an increase rate of remnant liver volume (IR-RLV) ≥ 40% and a minimal hypertrophy group (MH; n = 33) with an IR-RLV < 40%. We investigated the hemodynamics of portal venous flow after PTPE and the favorable factors for hepatic hypertrophy. RESULTS: Univariate and multivariate analysis identified the indocyanine green retention rate at 15 min (ICGR15) and increase rate of portal venous flow volume (IR-pFV) at the non-embolized lobe on day 3 after PTPE as independent favorable factors of IR-RLV. Patients with IR-pFV on day 3 after PTPE ≥100% and ICGR15 ≤ 15% (n = 13) exhibited significantly increased IR-RLV compared with others (n = 35). CONCLUSIONS: Cases with high IR-pFV on day 3 after PTPE exhibited better hepatic hypertrophy. Preserved liver function and increased portal venous flow on day 3 were important.
  • Transparenchymal glissonean approach: a novel surgical technique for advanced perihilar bile duct cancer
    Hirofumi Kamachi, Toshiya Kamiyama, Yousuke Tsuruga, Tatsuya Orimo, Kenji Wakayama, Shingo Shimada, Tatsuhiko Kakisaka, Hideki Yokoo, Kenichiro Yamashita, Akinobu Taketomi
    Langenbeck's Archives of Surgery, 403, 3, 387, 394, Springer Verlag, 2018年05月01日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus
    Toshiya Kamiyama, Tatsuhiko Kakisaka, Tatsuya Orimo, Kenji Wakayama
    World Journal of Hepatology, 9, 36, 1296, 1304, Baishideng Publishing Group Co, 2017年12月28日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Clinicopathological Characteristics of Hepatocellular Carcinoma with Microscopic Portal Venous Invasion and the Role of Anatomical Liver Resection in These Cases
    Shingo Shimada, Toshiya Kamiyama, Hideki Yokoo, Tatsuya Orimo, Kenji Wakayama, Takahiro Einama, Tatsuhiko Kakisaka, Hirofumi Kamachi, Akinobu Taketomi
    WORLD JOURNAL OF SURGERY, 41, 8, 2087, 2094, 2017年08月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Hepatectomy for liver metastasis from gastrointestinal stromal tumor in the era of imatinib mesylate: a case series study.
    Kawamura N, Kamiyama T, Yokoo H, Kakisaka T, Orimo T, Wakayama K, Tsuruga Y, Kamachi H, Hatanaka K, Taketomi A
    International cancer conference journal, 6, 3, 121, 125, 2017年07月, [査読有り], [国際誌]
    英語, The prognosis of metastatic gastrointestinal stromal tumor (GIST) has improved since the introduction of imatinib mesylate; however, acquired resistance has been reported, so alternative treatment option is needed. We evaluated the efficacy of hepatectomy for metastatic GIST. Six patients with liver metastases from GIST underwent hepatectomy. Four were treated with imatinib mesylate before hepatectomy, and all the patients were treated with imatinib mesylate after hepatectomy. Patients were followed-up for a mean duration of 113.5 months after hepatectomy. Complete resection was accomplished in four patients, with incomplete resection performed in the remaining two patients due to peritoneal dissemination. One patient with incomplete resection died 10 months after surgery. One patient with complete resection has survived without disease progression since initial hepatectomy. The remaining four patients with progressive disease during imatinib mesylate treatment developed tumor recurrence and three of them underwent a second hepatectomy. These three patients underwent complete resection during repeat surgery. In total, three patients died during the follow-up period, all of whom had tumors of small intestine origin. Primary tumor site (small intestine vs. others) was identified as a risk factor of mortality (P = 0.02). Although not statistically significant, there was a trend toward better outcomes in patients with exon 11 mutations. Surgical resection for metastatic GIST was shown to be effective and needed to achieve a better prognosis. Repeat hepatectomy demonstrated efficacy in selected patients. Hepatectomy should be considered based on tumor characteristics such as primary tumor site and c-KIT mutation status.
  • Fatty acid-binding protein 5 function in hepatocellular carcinoma through induction of epithelial-mesenchymal transition
    Ohata T, Yokoo H, Kamiyama T, Fukai M, Aiyama T, Hatanaka Y, Hatanaka K, Wakayama K, Orimo T, Kakisaka T, Kobayashi N, Matsuno Y, Taketomi A
    Cancer Medicine, 6, 5, 1049, 1061, 2017年04月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Hepatocellular carcinoma (HCC) is a highly prevalent cancer with poor prognosis. The correlation between overexpression of fatty acid-binding protein 5 (FABP5) and malignant potential of tumor growth and metastasis in several cancers has been previously reported. However, the correlation between FABP5 expression and HCC malignant behavior remains unknown. We compared FABP5 expression and patient characteristics in paired HCC and adjacent noncancerous liver tissues from 243 patients who underwent surgical resection of primary HCC. Cell proliferation, invasion, and migration assays were performed in HCC cell lines overexpressing FABP5 or downregulated for FABP5. Tumor growths were monitored in xenograft model, and liver and lung metastasis models were established. In the 243 HCC patients, FABP5-positive staining (n = 139/243, 57.2%) was associated with poor prognosis and recurrence (P < 0.0001) and showed positive correlation with distant metastasis, tumor size and vascular invasion (P < 0.05). Cell proliferation, invasion, and migration in vitro were enhanced by upregulation of FABP5 and decreased by downregulation of FABP5 in HCC cell lines. Similar results in tumor formation and metastasis were obtained through in vivo analyses. PCR array results revealed upregulation of SNAI1 in FABP5-overexpressing HepG2 cells. Western blot analysis showed significantly increased expression of E-cadherin and ZO-1 and decreased SNAI1 expression and nuclear translocation of β-catenin by knockdown of FABP5. We revealed a significant role for FABP5 in HCC progression and metastasis through the induction of epithelial-to-mesenchymal transition. FABP5 may be a potential novel prognostic biomarker and new therapeutic target for HCC.
  • [Analysis of Oxaliplatin Combination Therapy for Unresectable or Recurrent Gastric Cancer].
    Yoshinori Oikawa, Masahiro Takahashi, Shusaku Takahashi, Satoru Matsumoto, Sachiko Kenno, Keita Noguchi, Tatsuhiko Kakisaka, Munenori Tahara, Hideki Yamagami, Hiroyuki Ishizu
    Gan to kagaku ryoho. Cancer & chemotherapy, 43, 12, 1579, 1581, 2016年11月, [国内誌]
    日本語, 研究論文(学術雑誌), We analyzed 26 cases of unresectable or recurrent gastric cancer treated with oxaliplatin(OX)combination therapy between September 2014 and January 2016. The number of unresectable gastric cancer cases was 14 and there were 12 recurrent cases. The number of patients receiving S-1 plus OX(SOX), SOX plus trastuzumab(Tmab), capecitabine(Cape)plus OX(CapeOX), and CapeOX plus Tmab was 17, 1, 6, and 2, respectively. The starting dose of OX was 130mg/m2 in 12 patients and 100mg/m2 in 14. The median follow-up duration from the first treatment was 6 months(1-14). The median number of treatment cycles was 5(1-19). Dose reductions occurred in 14 cases, and treatment delay occurred in 13 cases. Grade 3 adverse events occurred in 2 cases(8%); thrombocytopenia and stomatitis occurred in 1 case. The response rate was 23%, the disease control rate was 69%, and the median relapse-free survival time was 4 months(1-14). OX combination therapy for unresectable or recurrent gastric cancer was feasible in terms of safety and might be effective for disease control.
  • Our technique of preceding diaphragm resection and partial mobilization of the hepatic right lobe using a vessel sealing device (LigaSure™) for huge hepatic tumors with diaphragm invasion.
    Wakayama K, Kamiyama T, Yokoo H, Kakisaka T, Orimo T, Shimada S, Tsuruga Y, Kamachi H, Taketomi A
    Surgery today, 46, 10, 1224, 1229, Springer Tokyo, 2016年10月01日, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌)
  • ZEB1 expression is associated with prognosis of intrahepatic cholangiocarcinoma
    Katsumi Terashita, Makoto Chuma, Yutaka Hatanaka, Kanako Hatanaka, Tomoko Mitsuhashi, Hideki Yokoo, Takumi Ohmura, Hiroyuki Ishizu, Shunji Muraoka, Atsushi Nagasaka, Takahiro Tsuji, Yoshiya Yamamoto, Nobuaki Kurauchi, Norihiko Shimoyama, Hidenori Toyoda, Takashi Kumada, Yuji Kaneoka, Atsuyuki Maeda, Koji Ogawa, Mitsuteru Natsuizaka, Hirofumi Kamachi, Tatsuhiko Kakisaka, Toshiya Kamiyama, Akinobu Taketomi, Yoshihiro Matsuno, Naoya Sakamoto
    Journal of Clinical Pathology, 69, 7, 593, 599, BMJ Publishing Group, 2016年07月01日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Significance of functional hepatic resection rate calculated using 3D CT/99mTc-galactosyl human serum albumin singlephoton emission computed tomography fusion imaging
    Yosuke Tsuruga, Toshiya Kamiyama, Hirofumi Kamachi, Shingo Shimada, Kenji Wakayama, Tatsuya Orimo, Tatsuhiko Kakisaka, Hideki Yokoo, Akinobu Taketomi
    World Journal of Gastroenterology, 22, 17, 4373, 4379, Baishideng Publishing Group Co., Limited, 2016年05月07日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Resection of liver metastasis derived from alpha-fetoprotein-producing gastric cancer-report of 4 cases
    Asahi Yoh, Kamiyama Toshiya, Homma Shigenori, Hatanaka Kanako C, Yokoo Hideki, Nakagawa Takahito, Kamachi Hirofumi, Nakanishi Kazuaki, Tahara Munenori, Kakisaka Tatsuhiko, Wakayama Kenji, Todo Satoru, Taketomi Akinobu
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 5, 2, 98, 103, 2016年04月, [査読有り], [国際誌]
    英語
  • Anatomical hepatectomy using indocyanine green fluorescent imaging and needle- guiding technique
    Toshiya Kamiyama, Tatsuhiko Kakisaka, Hideki Yokoo, Tatsuya Orimo, Kenji Wakayama, Hirofumi Kamachi, Yosuke Tsuruga, Akinobu Taketomi
    ICG Fluorescence Imaging and Navigation Surgery, 305, 313, Springer Japan, 2016年01月01日, [査読有り]
    英語, 論文集(書籍)内論文
  • Models predicting the risks of six life-threatening morbidities and bile leakage in 14,970 hepatectomy patients registered in the National Clinical Database of Japan
    Hideki Yokoo, Hiroaki Miyata, Hiroyuki Konno, Akinobu Taketomi, Tatsuhiko Kakisaka, Norimichi Hirahara, Go Wakabayashi, Mitsukazu Gotoh, Masaki Mori
    Medicine (United States), 95, 49, e5466, Lippincott Williams and Wilkins, 2016年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • [Efficacy of Sorafenib for Extrahepatic Recurrence of Hepatocellular Carcinoma after Liver Resection].
    Yokoo H, Kamiyama T, Kakisaka T, Orimo T, Wakayama K, Shimada S, Tsuruga Y, Kamachi H, Taketomi A
    Gan to kagaku ryoho. Cancer & chemotherapy, 42, 12, 1497, 1499, 2015年11月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌), Sorafenib is the first molecularly targeted drug recommended as a treatment for advanced hepatocellular carcinoma (HCC). Herein, we report the efficacy of sorafenib for extrahepatic recurrence of HCC. From September 2004 to March 2015, 47 patients who were diagnosed with recurrent HCC after liver resection were treated with sorafenib. The overall response rate was 17.5% (complete response: CR 1, partial response: PR 6, stable disease: SD 17, progressive disease: PD 13, SD beyond PD 3), and the disease control rate was 67.5%. The median time to disease progression, including extrahepatic recurrence, was significantly better than in the group with only intrahepatic metastasis (p=0.034). Therefore, sorafenib might be an effective treatment for extrahepatic recurrence of HCC.
  • [Effect of Preoperative Bowel Preparation on Surgical Site Infection in Liver Surgery].
    Orimo T, Kamiyama T, Yokoo H, Kakisaka T, Wakayama K, Tsuruga Y, Kamachi H, Taketomi A
    Gan to kagaku ryoho. Cancer & chemotherapy, 42, 12, 1887, 1889, (株)癌と化学療法社, 2015年11月, [査読有り], [国内誌]
    日本語
  • Multiplication of alpha-fetoprotein and protein induced by vitamin K absence-II is a powerful predictor of prognosis and recurrence in hepatocellular carcinoma patients after a hepatectomy
    Toshiya Kamiyama, Hideki Yokoo, Tatsuhiko Kakisaka, Tatsuya Orimo, Kenji Wakayama, Hirofumi Kamachi, Yosuke Tsuruga, Kenichiro Yamashita, Tsuyoshi Shimamura, Satoru Todo, Akinobu Taketomi
    HEPATOLOGY RESEARCH, 45, 10, E21, E31, 2015年10月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Intratumoral artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma
    Seiji Tsunematsu, Makoto Chuma, Toshiya Kamiyama, Noriyuki Miyamoto, Satoshi Yabusaki, Kanako Hatanaka, Tomoko Mitsuhashi, Hirofumi Kamachi, Hideki Yokoo, Tatsuhiko Kakisaka, Yousuke Tsuruga, Tatsuya Orimo, Kenji Wakayama, Jun Ito, Fumiyuki Sato, Katsumi Terashita, Masato Nakai, Yoko Tsukuda, Takuya Sho, Goki Suda, Kenichi Morikawa, Mitsuteru Natsuizaka, Mitsuru Nakanishi, Koji Ogawa, Akinobu Taketomi, Yoshihiro Matsuno, Naoya Sakamoto
    ABDOMINAL IMAGING, 40, 6, 1492, 1499, 2015年08月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • 膵癌術前放射線化学療法における術前胆道ドレナージ法の検討               
    敦賀 陽介, 蒲池 浩文, 若山 顕治, 折茂 達也, 柿坂 達彦, 横尾 英樹, 神山 俊哉, 武冨 紹信
    日本肝胆膵外科学会・学術集会プログラム・抄録集, 27回, 626, 626, (一社)日本肝胆膵外科学会, 2015年06月
    日本語
  • [Intra-arterial infusion of IA-call® combined with oral anticancer drugs for recurrent hepatocellular carcinoma after liver resection].
    Wakayama K, Kamiyama T, Yokoo H, Kakisaka T, Orimo T, Tsuruga Y, Kamachi H, Soyama T, Sakuhara Y, Abo D, Taketomi A
    Gan to kagaku ryoho. Cancer & chemotherapy, 41, 12, 1503, 1505, Japanese Journal of Cancer and Chemotherapy Publishers Inc., 2014年11月01日, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌)
  • 巨大肝細胞癌手術症例の治療成績               
    柿坂 達彦, 神山 俊哉, 横尾 英樹, 折茂 達也, 若山 顕治, 敦賀 陽介, 蒲池 浩文, 武冨 紹信
    Japanese Journal of Acute Care Surgery, 4, 2, 304, 304, 日本Acute Care Surgery学会, 2014年09月
    日本語
  • Hand-assisted laparoscopic splenectomy for sclerosing angiomatoid nodular transformation of the spleen complicated by chronic disseminated intravascular coagulation: A case report
    Tatsuhiko Kakisaka, Toshiya Kamiyama, Hideki Yokoo, Tatsuya Orimo, Kenji Wakayama, Yosuke Tsuruga, Hirofumi Kamachi, Taisuke Harada, Fumi Kato, Yosuke Yamada, Tomoko Mitsuhashi, Akinobu Taketomi
    Asian Journal of Endoscopic Surgery, 7, 3, 275, 278, Wiley, 2014年08月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), A 36-year-old man who presented with a nosebleed and anemia was referred to our hospital. Laboratory test results showed platelet depletion, decreased levels of fibrinogen, and increased fibrinogen degeneration products. CT showed a 13-cm splenic tumor. T2 -weighted MRI revealed a high-intensity mass. We preoperatively diagnosed splenic hemangioma with chronic disseminated intravascular coagulation and scheduled an operation to relieve the disseminated intravascular coagulation. We also performed hand-assisted laparoscopic splenectomy to ensure easy handling of the splenomegaly. The resected specimen microscopically consisted of hemorrhages and hemangiomatous lesions, and multiple angiomatoid nodules were scattered and separated by fibrocollagenous stroma with inflammatory cells. Three types of vessels (capillaries, sinusoids and small veins) were contained in the angiomatoid nodules, and the pathological diagnosis was sclerosing angiomatoid nodular transformation. The results of this case suggest that we should consider sclerosing angiomatoid nodular transformation in the differential diagnosis of patients with splenic tumors, as sclerosing angiomatoid nodular transformation with hemangiomatous features may cause coagulation disorders for which splenectomy should be performed.
  • ICG蛍光法とニードルガイディングテクニックを併用した肝亜区域切除術               
    折茂 達也, 神山 俊哉, 横尾 英樹, 柿坂 達彦, 若山 顕治, 敦賀 陽介, 蒲池 浩文, 武冨 紹信
    日本消化器外科学会総会, 69回, RV, 1, (一社)日本消化器外科学会, 2014年07月
    日本語
  • 99mTc-GSAシンチグラフィーとCTの3D fusion画像を用いた残肝機能予測               
    敦賀 陽介, 蒲池 浩文, 若山 顕治, 折茂 達也, 柿坂 達彦, 横尾 英樹, 神山 俊哉, 武冨 紹信
    日本消化器外科学会総会, 69回, O, 5, (一社)日本消化器外科学会, 2014年07月
    日本語
  • 肝切除術におけるリスク評価と治療成績向上に向けた対策 NCDデータに基づいた肝切除術におけるリスク評価               
    武冨 紹信, 宮田 裕章, 柿坂 達彦, 横尾 英樹, 友滝 愛, 今野 弘之, 後藤 満一, 若林 剛, 森 正樹, 一般社団法人日本消化器外科学会データベース委員会
    日本消化器外科学会総会, 69回, PD, 1, (一社)日本消化器外科学会, 2014年07月
    日本語
  • 肝切除術におけるリスク評価と治療成績向上に向けた対策 99mTc-GSAシンチグラフィを用いた肝障害度別換算ICGR15による肝予備能の評価               
    若山 顕治, 神山 俊哉, 柿坂 達彦, 折茂 達也, 横尾 英樹, 敦賀 陽介, 蒲池 浩文, 武冨 紹信
    日本消化器外科学会総会, 69回, PD, 5, (一社)日本消化器外科学会, 2014年07月
    日本語
  • HBV関連肝細胞癌手術症例の術後再発に関する検討               
    柿坂 達彦, 神山 俊哉, 横尾 英樹, 折茂 達也, 若山 顕治, 敦賀 陽介, 蒲池 浩文, 武冨 紹信
    日本消化器外科学会総会, 69回, P, 3, (一社)日本消化器外科学会, 2014年07月
    日本語
  • 肝細胞癌における門脈侵襲・予後・再発予測因子としての腫瘍マーカー AFPとPIVKA-IIの積=AP-factorの検討               
    神山 俊哉, 横尾 英樹, 柿坂 達彦, 折茂 達也, 若山 顕治, 蒲池 浩文, 敦賀 陽介, 武冨 紹信
    日本消化器外科学会総会, 69回, P, 6, (一社)日本消化器外科学会, 2014年07月
    日本語
  • 大腸癌多発肝転移に対する外科切除のタイミング               
    横尾 英樹, 神山 俊哉, 柿坂 達彦, 折茂 達也, 若山 顕治, 敦賀 陽介, 蒲池 浩文, 武冨 紹信
    日本消化器外科学会総会, 69回, O, 2, (一社)日本消化器外科学会, 2014年07月
    日本語
  • 血管合併切除を要する局所進行肝門部胆管癌における血管確保手技               
    蒲池 浩文, 敦賀 陽介, 若山 顕示, 折茂 達也, 柿坂 達彦, 横尾 英樹, 山下 健一郎, 神山 俊哉, 武冨 紹信
    日本消化器外科学会総会, 69回, O, 1, (一社)日本消化器外科学会, 2014年07月
    日本語
  • 浸潤性膵管癌の術前治療 当科における局所進行膵癌に対する術前放射線化学療法の検討               
    蒲池 浩文, 敦賀 陽介, 若山 顕治, 折茂 達也, 柿坂 達彦, 横尾 英樹, 神山 俊哉, 武冨 紹信
    日本肝胆膵外科学会・学術集会プログラム・抄録集, 26回, 387, 387, (一社)日本肝胆膵外科学会, 2014年06月
    日本語
  • 肝右葉巨大肝癌に対する、ベッセルシーリングシステムを用いた右横隔膜切除、肝右葉受動先行右系肝葉切除               
    若山 顕治, 神山 俊哉, 横尾 英樹, 柿坂 達彦, 折茂 達也, 敦賀 陽介, 蒲池 浩文, 武冨 紹信
    日本肝胆膵外科学会・学術集会プログラム・抄録集, 26回, 448, 448, (一社)日本肝胆膵外科学会, 2014年06月
    日本語
  • 99mTc-GSAシンチグラフィーとCTの3D fusion画像を用いた機能的肝切除率の算出               
    敦賀 陽介, 蒲池 浩文, 若山 顕治, 折茂 達也, 柿坂 達彦, 横尾 英樹, 神山 俊哉, 武冨 紹信
    日本肝胆膵外科学会・学術集会プログラム・抄録集, 26回, 484, 484, (一社)日本肝胆膵外科学会, 2014年06月
    日本語
  • 多発性大腸癌肝転移の治療方針               
    横尾 英樹, 神山 俊哉, 柿坂 達彦, 折茂 達也, 若山 顕治, 敦賀 陽介, 蒲池 浩文, 武冨 紹信
    日本肝胆膵外科学会・学術集会プログラム・抄録集, 26回, 549, 549, (一社)日本肝胆膵外科学会, 2014年06月
    日本語
  • 人工血管を用いた肝切除症例の検討               
    折茂 達也, 神山 俊哉, 横尾 英樹, 柿坂 達彦, 若山 顕治, 敦賀 陽介, 蒲池 浩文, 武冨 紹信
    日本肝胆膵外科学会・学術集会プログラム・抄録集, 26回, 588, 588, (一社)日本肝胆膵外科学会, 2014年06月
    日本語
  • 肝エキノコックス症に対する腹腔鏡下肝切除術               
    柿坂 達彦, 神山 俊哉, 横尾 英樹, 折茂 達也, 若山 顕治, 敦賀 陽介, 蒲池 浩文, 武冨 紹信
    日本肝胆膵外科学会・学術集会プログラム・抄録集, 26回, 686, 686, (一社)日本肝胆膵外科学会, 2014年06月
    日本語
  • 当科における肝細胞癌に対する腹腔鏡下肝切除術の成績               
    柿坂 達彦, 神山 俊哉, 横尾 英樹, 折茂 達也, 若山 顕治, 敦賀 陽介, 蒲池 浩文, 武冨 紹信
    日本癌治療学会誌, 49, 3, 1669, 1669, (一社)日本癌治療学会, 2014年06月
    日本語
  • 横行結腸癌肝転移切除後断端再発に対し施行したRFA後に、biloma内再発をきたした1例
    深作 慶友, 神山 俊哉, 若山 顕治, 折茂 達也, 敦賀 陽介, 柿坂 達彦, 横尾 英樹, 蒲池 浩文, 武富 紹信
    北海道外科雑誌, 59, 1, 62, 62, 北海道外科学会, 2014年06月
    日本語
  • A pilot study for cellular detection of circulating tumor cells and disseminated tumor cells of patients with hepatocellular carcinoma.
    Nozomi Minagawa, Hideyasu Sakihama, Nozomi Kobayashi, Mito Obara, Susumu Shibasaki, Kenji Wakayama, Tatsuya Orimo, Tatsuhiko Kakisaka, Yousuke Tsuruga, Shigenori Homma, Hideki Yokoo, Hirofumi Kamachi, Hideki Kawamura, Norihiko Takahashi, Toshiya Kamiyama, Akinobu Taketomi
    JOURNAL OF CLINICAL ONCOLOGY, 32, 15, 2014年05月, [査読有り]
    英語
  • Usefulness of artificial vascular graft for venous reconstruction in liver surgery
    Tatsuya Orimo, Toshiya Kamiyama, Hideki Yokoo, Tatsuhiko Kakisaka, Kenji Wakayama, Yosuke Tsuruga, Hirofumi Kamachi, Akinobu Taketomi
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 12, 113, 113, 2014年04月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Long-Term Outcome of Laparoscopic Hepatectomy in Patients with Hepatocellular Carcinoma
    Toshiya Kamiyama, Munenori Tahara, Kazuaki Nakanishi, Hideki Yokoo, Hirofumi Kamachi, Tatsuhiko Kakisaka, Yosuke Tsuruga, Michiaki Matsushita, Satoru Todo
    HEPATO-GASTROENTEROLOGY, 61, 130, 405, 409, 2014年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • 人工血管による肝静脈再建を伴う肝切除術を施行した肝細胞癌の2例
    折茂 達也, 神山 俊哉, 横尾 英樹, 柿坂 達彦, 若山 顕治, 敦賀 陽介, 蒲池 浩文, 武冨 紹信
    北海道外科雑誌, 58, 2, 181, 181, 北海道外科学会, 2013年12月
    日本語
  • 肝原発腺扁平上皮癌の1例
    宮岡 陽一, 神山 俊哉, 横尾 英樹, 柿坂 達彦, 折茂 達也, 若山 顕治, 敦賀 陽介, 蒲池 浩文, 武冨 紹信, 畑中 佳奈子
    北海道外科雑誌, 58, 2, 182, 183, 北海道外科学会, 2013年12月
    日本語
  • 当科における胆管癌再発症例の検討
    敦賀 陽介, 蒲池 浩文, 若山 顕治, 折茂 達也, 柿坂 達彦, 横尾 英樹, 神山 俊哉, 武冨 紹信
    北海道外科雑誌, 58, 2, 184, 184, 北海道外科学会, 2013年12月
    日本語
  • [Long-term survival of a patient with metachronous lymph node metastasis and bile duct tumor thrombus due to hepatocellular carcinoma successfully treated with repeated surgery].
    Kakisaka T, Kamiyama T, Yokoo H, Orimo T, Wakayama K, Tsuruga Y, Kamachi H, Hatanaka K, Taketomi A
    Gan to kagaku ryoho. Cancer & chemotherapy, 40, 12, 1831, 1833, 12, 2013年11月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌), A 64-year-old man with hepatocellular carcinoma located in the left lateral lobe and segment 5 was referred to our hospital for surgical treatment. We performed left lateral sectionectomy and segmentectomy 5. The pathological diagnosis was moderately to poorly differentiated hepatocellular carcinoma, and the pathological stage was stage III. Eight months later, intrahepatic recurrence in segment 1 and lymph node metastasis in the hepatoduodenal ligament occurred. Partial resection of segment 1 was performed, and the metastatic lymph node was surgically removed. Twenty four months after the first operation, lymph node metastases along the lesser curvature and retropancreatic space were extirpated. Lymph node metastases along the common hepatic artery were removed 76 months after the first operation. The patient developed jaundice 88 months after the initial surgery, and the bile duct tumor thrombus derived from intrahepatic recurrence in segment 1 caused obstructive jaundice. After percutaneous transhepatic biliary drainage, we performed median sectionectomy and bile duct tumor thrombus removal without bile duct resection. At his 8-year follow-up visit after the primary operation, the patient was healthy and did not show any signs of recurrence. Lymph node metastasis and bile duct tumor thrombus are rare patterns of hepatocellular carcinoma recurrence, and aggressive surgery can result in long-term survival when complete resection is anticipated.
  • Surgical management of hepatocellular carcinoma with tumor thrombi in the inferior vena cava or right atrium
    Kenji Wakayama, Toshiya Kamiyama, Hideki Yokoo, Tatsuhiko Kakisaka, Hirofumi Kamachi, Yosuke Tsuruga, Kazuaki Nakanishi, Tsuyoshi Shimamura, Satoru Todo, Akinobu Taketomi
    World Journal of Surgical Oncology, 11, 259, 259, 2013年10月05日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • 断端陽性となった肝門部胆管癌に対する術後放射線療法の意義               
    蒲池 浩文, 敦賀 陽介, 若山 顕治, 折茂 達也, 柿坂 達彦, 横尾 英樹, 神山 俊哉, 武冨 紹信
    日本臨床外科学会雑誌, 74, 増刊, 617, 617, 日本臨床外科学会, 2013年10月
    日本語
  • 肝細胞癌肺転移切除後19年間無再発の一例               
    相山 健, 神山 俊哉, 横尾 英樹, 柿坂 達彦, 折茂 達也, 若山 顕治, 敦賀 陽介, 蒲池 浩文, 武富 紹信
    日本癌治療学会誌, 48, 3, 2409, 2409, (一社)日本癌治療学会, 2013年09月
    日本語
  • 肝細胞癌における予後再発因子としてのFABP5の有用性               
    大畑 多嘉宣, 横尾 英樹, 柿坂 達彦, 敦賀 陽介, 蒲池 浩文, 神山 俊哉, 武冨 紹信
    日本消化器外科学会総会, 68回, P, 8, (一社)日本消化器外科学会, 2013年07月
    日本語
  • 肝尾状葉腫瘍切除における3D画像によるシミュレーションの有用性               
    若山 顕治, 神山 俊哉, 柿坂 達彦, 横尾 英樹, 敦賀 陽介, 蒲池 浩文, 武冨 紹信
    日本消化器外科学会総会, 68回, O, 3, (一社)日本消化器外科学会, 2013年07月
    日本語
  • 左葉系切除を要する高度進行胆道癌に対するTransparenchymal glissonean approachを用いた血行再建法               
    蒲池 浩文, 敦賀 陽介, 若山 顕治, 柿坂 達彦, 横尾 英樹, 山下 健一郎, 神山 俊哉, 武冨 紹信
    日本消化器外科学会総会, 68回, RV, 3, (一社)日本消化器外科学会, 2013年07月
    日本語
  • 血清中糖鎖の網羅的解析による肝細胞癌新規バイオマーカーの開発               
    神山 俊哉, 柿坂 達彦, 横尾 英樹, 蒲池 浩文, 若山 顕治, 敦賀 陽介, 三浦 信明, 西村 紳一郎, 藤堂 省, 武冨 紹信
    日本消化器外科学会総会, 68回, O, 5, (一社)日本消化器外科学会, 2013年07月
    日本語
  • Identification of novel serum biomarkers of hepatocellular carcinoma using glycomic analysis
    Toshiya Kamiyama, Hideki Yokoo, Jun-Ichi Furukawa, Masaki Kurogochi, Tomoaki Togashi, Nobuaki Miura, Kazuaki Nakanishi, Hirofumi Kamachi, Tatsuhiko Kakisaka, Yosuke Tsuruga, Masato Fujiyoshi, Akinobu Taketomi, Shin-Ichiro Nishimura, Satoru Todo
    HEPATOLOGY, 57, 6, 2314, 2325, 2013年06月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • An intraductal papillary neoplasm of the bile duct mimicking a hemorrhagic hepatic cyst: a case report
    Tatsuhiko Kakisaka, Toshiya Kamiyama, Hideki Yokoo, Kazuaki Nakanishi, Kenji Wakayama, Yosuke Tsuruga, Hirofumi Kamachi, Tomoko Mitsuhashi, Akinobu Taketomi
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 11, 111, 111, 2013年05月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • A pilot study for cellular detection of circulating tumor cells and disseminated tumor cells of patients with hepatocellular carcinoma.
    Nozomi Minagawa, Hideyasu Sakihama, Nozomi Kobayashi, Kenji Wakayama, Tatsuhiko Kakisaka, Yousuke Tsuruga, Tatsushi Shimokuni, Shigenori Homma, Hideki Yokoo, Hirofumi Kamachi, Norihiko Takahashi, Toshiya Kamiyama, Akinobu Taketomi
    JOURNAL OF CLINICAL ONCOLOGY, 31, 15, 2013年05月, [査読有り]
    英語
  • Portal vein stenosis after pancreatectomy following neoadjuvant chemoradiation therapy for pancreatic cancer
    Yosuke Tsuruga, Hirofumi Kamachi, Kenji Wakayama, Tatsuhiko Kakisaka, Hideki Yokoo, Toshiya Kamiyama, Akinobu Taketomi
    WORLD JOURNAL OF GASTROENTEROLOGY, 19, 16, 2569, 2573, 2013年04月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Clinicopathological characteristics and prognostic factors in young patients after hepatectomy for hepatocellular carcinoma
    Shingo Shimada, Toshiya Kamiyama, Hideki Yokoo, Kenji Wakayama, Yosuke Tsuruga, Tatsuhiko Kakisaka, Hirofumi Kamachi, Akinobu Taketomi
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 11, 52, 52, 2013年03月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • 胆道癌手術に有用な外科解剖と画像診断 肝門部領域胆道系腫瘍に対する胆管・血管3DCT合成画像の治療戦略上の位置づけ
    蒲池 浩文, 敦賀 陽介, 若山 顕治, 柿坂 達彦, 横尾 英樹, 山下 健一郎, 神山 俊哉, 武冨 紹信
    日本外科学会雑誌, 114, 臨増2, 146, 146, (一社)日本外科学会, 2013年03月
    日本語
  • 腹腔鏡下肝切除の現状と適応拡大の試み 適応拡大を目指した腹腔鏡下肝切除における肝門部処理・肝実質切離法の確立
    神山 俊哉, 横尾 英樹, 柿坂 達彦, 若山 顕治, 敦賀 陽介, 蒲池 浩文, 武冨 紹信
    日本外科学会雑誌, 114, 臨増2, 201, 201, (一社)日本外科学会, 2013年03月
    日本語
  • 肝静脈解剖に注目した肝切除 3D画像支援システムによる下右肝静脈還流領域を評価した肝切除
    横尾 英樹, 神山 俊哉, 柿坂 達彦, 若山 顕治, 敦賀 陽介, 蒲池 浩文, 武冨 紹信
    日本外科学会雑誌, 114, 臨増2, 211, 211, (一社)日本外科学会, 2013年03月
    日本語
  • 肝エキノコッカス症と鑑別困難であったMulticystic billary hamartomaの一例               
    本間 友樹, 武冨 紹信, 神山 俊哉, 蒲池 浩文, 横尾 英樹, 柿坂 達彦, 敦賀 陽介, 若山 顕治
    日本臨床外科学会雑誌, 74, 2, 595, 595, 日本臨床外科学会, 2013年02月
    日本語
  • 大腸癌肝転移に対するRFA後再発の2例               
    石黒 友唯, 中西 一彰, 横尾 英樹, 柿坂 達彦, 敦賀 陽介, 蒲池 浩文, 神山 俊哉
    IVR: Interventional Radiology, 27, 4, 457, 458, (一社)日本インターベンショナルラジオロジー学会, 2012年11月
    日本語
  • Liver hanging maneuverとその応用 肝門部胆管癌におけるLiver hanging maneuverを応用した肝実質切離               
    蒲池 浩文, 敦賀 陽介, 若山 顕治, 柿坂 達彦, 横尾 英樹, 神山 俊哉, 武冨 紹信
    日本臨床外科学会雑誌, 73, 増刊, 379, 379, 日本臨床外科学会, 2012年10月
    日本語
  • 肝尾状葉腫瘍切除における3次元画像解析システムの有用性               
    若山 顕治, 神山 俊哉, 横尾 英樹, 柿坂 達彦, 蒲池 浩文, 敦賀 陽介, 武富 紹信
    日本臨床外科学会雑誌, 73, 増刊, 694, 694, 日本臨床外科学会, 2012年10月
    日本語
  • 血管合併切除を伴う術前放射線化学療法施行後膵癌根治切除症例の検討               
    敦賀 陽介, 蒲池 浩文, 若山 顕治, 柿坂 達彦, 横尾 英樹, 神山 俊哉, 武富 紹信
    日本臨床外科学会雑誌, 73, 増刊, 767, 767, 日本臨床外科学会, 2012年10月
    日本語
  • 当科における胆道嚢胞性疾患症例の検討               
    敦賀 陽介, 蒲池 浩文, 柿坂 達彦, 横尾 英樹, 中西 一彰, 神山 俊哉, 武冨 紹信
    日本消化器外科学会総会, 67回, 2, 2, (一社)日本消化器外科学会, 2012年07月
    日本語
  • 予後、再発因子からみた肝内胆管癌の治療戦略               
    横尾 英樹, 神山 俊哉, 中西 一彰, 柿坂 達彦, 敦賀 陽介, 蒲池 浩文, 武冨 紹信
    日本消化器外科学会総会, 67回, 1, 1, (一社)日本消化器外科学会, 2012年07月
    日本語
  • 腹腔鏡下・補助下肝切除術における肝実質切離の工夫と定型化               
    神山 俊哉, 中西 一彰, 横尾 英樹, 柿坂 達彦, 敦賀 陽介, 蒲池 浩文, 武冨 紹信
    日本消化器外科学会総会, 67回, 1, 1, (一社)日本消化器外科学会, 2012年07月
    日本語
  • 肝細胞癌遠隔転移切除症例の検討               
    中西 一彰, 神山 俊哉, 横尾 英樹, 柿坂 達彦, 敦賀 陽介, 蒲池 浩文, 武冨 紹信
    日本消化器外科学会総会, 67回, 2, 2, (一社)日本消化器外科学会, 2012年07月
    日本語
  • 肝門部領域胆道系腫瘍における胆管・血管3DCT合成画像を用いた手術シミュレーション               
    蒲池 浩文, 敦賀 陽介, 柿坂 達彦, 横尾 英樹, 中西 一彰, 神山 俊哉, 武冨 紹信
    日本消化器外科学会総会, 67回, 1, 1, (一社)日本消化器外科学会, 2012年07月
    日本語
  • 超高齢者の肝細胞癌手術症例に関する検討               
    柿坂 達彦, 神山 俊哉, 中西 一彰, 横尾 英樹, 蒲池 浩文, 敦賀 陽介, 武冨 紹信
    日本消化器外科学会総会, 67回, 1, 1, (一社)日本消化器外科学会, 2012年07月
    日本語
  • Analysis of the risk factors for early death due to disease recurrence or progression within 1 year after hepatectomy in patients with hepatocellular carcinoma
    Toshiya Kamiyama, Kazuaki Nakanishi, Hideki Yokoo, Hirofumi Kamachi, Munenori Tahara, Tatsuhiko Kakisaka, Yosuke Tsuruga, Satoru Todo, Akinobu Taketomi
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 10, 107, 107, 2012年06月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • 後腹膜巨大脂肪肉腫の一切除例               
    豊島 雄二郎, 中西 一彰, 横尾 英樹, 柿坂 達彦, 敦賀 陽介, 蒲池 浩文, 松下 通明, 神山 俊哉
    日本臨床外科学会雑誌, 73, 6, 1599, 1599, 日本臨床外科学会, 2012年06月
    日本語
  • 減量手術の肝エキノコックス症に対しアルベンダゾールが著効した1例               
    梅本 浩平, 横尾 英樹, 中西 一彰, 柿坂 達彦, 敦賀 陽介, 蒲池 浩文, 佐藤 直樹, 神山 俊哉
    日本臨床外科学会雑誌, 73, 6, 1602, 1602, 日本臨床外科学会, 2012年06月
    日本語
  • 膵・胆管合流異常を伴う先天性胆道拡張症に対する分流手術後に発生した胆管癌の1例               
    岡田 尚樹, 蒲池 浩文, 敦賀 陽介, 柿坂 達彦, 横尾 英樹, 中西 一彰, 松下 通明, 神山 俊哉
    日本臨床外科学会雑誌, 73, 6, 1604, 1604, 日本臨床外科学会, 2012年06月
    日本語
  • 胆管空腸吻合術後の肝内結石症に対する肝切除術の検討
    敦賀 陽介, 蒲池 浩文, 柿坂 達彦, 横尾 英樹, 中西 一彰, 神山 俊哉, 武冨 紹信
    北海道外科雑誌, 57, 1, 74, 74, 北海道外科学会, 2012年06月
    日本語
  • HBs抗原陰性・HCV抗体陰性肝細胞癌切除例の検討
    中西 一彰, 神山 俊哉, 横尾 英樹, 柿坂 達彦, 敦賀 陽介, 蒲池 浩文, 武冨 紹信
    北海道外科雑誌, 57, 1, 74, 75, 北海道外科学会, 2012年06月
    日本語
  • 成人肝未分化肉腫の1例
    鈴木 智亮, 神山 俊哉, 中西 一彰, 横尾 英樹, 柿坂 達彦, 敦賀 陽介, 鈴木 崇史, 蒲池 浩文, 松下 通明, 武冨 紹信
    北海道外科雑誌, 57, 1, 75, 75, 北海道外科学会, 2012年06月
    日本語
  • 術後胆管狭窄に対する皮下埋め込み式胆道内瘻術の有用性
    川俣 太, 神山 俊哉, 中西 一彰, 横尾 英樹, 柿坂 達彦, 田原 宗徳, 蒲池 浩文, 松下 通明, 藤堂 省
    日本消化器外科学会雑誌, 45, 6, 615, 622, (一社)日本消化器外科学会, 2012年06月
    日本語
  • 肝胆膵領域の外科治療 これまでの到達点、これからの課題 肝細胞癌に対する肝切除術 系統的切除か部分切除か 小型肝細胞癌に対する系統的肝切除術の術後長期成績の検討               
    武冨 紹信, 神山 俊哉, 中西 一彰, 蒲池 浩文, 横尾 英樹, 柿坂 達彦, 敦賀 陽介
    日本肝胆膵外科学会・学術集会プログラム・抄録集, 24回, 195, 195, (一社)日本肝胆膵外科学会, 2012年05月
    日本語
  • 局所進行肝内胆管癌に対してR0をめざした下大静脈合併切除グラフト再建               
    横尾 英樹, 神山 俊哉, 中西 一彰, 柿坂 達彦, 敦賀 陽介, 蒲池 浩文, 武冨 紹信
    日本肝胆膵外科学会・学術集会プログラム・抄録集, 24回, 302, 302, (一社)日本肝胆膵外科学会, 2012年05月
    日本語
  • 再発形式からみた胆管癌治療戦略               
    敦賀 陽介, 蒲池 浩文, 柿坂 達彦, 横尾 英樹, 中西 一彰, 神山 俊哉, 武冨 紹信
    日本肝胆膵外科学会・学術集会プログラム・抄録集, 24回, 420, 420, (一社)日本肝胆膵外科学会, 2012年05月
    日本語
  • 血管合併切除を伴う肝門部領域胆道系癌に対する手術アプローチ               
    蒲池 浩文, 敦賀 陽介, 柿坂 達彦, 横尾 英樹, 中西 一彰, 神山 俊哉, 武冨 紹信
    日本肝胆膵外科学会・学術集会プログラム・抄録集, 24回, 420, 420, (一社)日本肝胆膵外科学会, 2012年05月
    日本語
  • 出血性肝嚢胞と鑑別を要した胆管内乳頭状腫瘍(IPNB)の1例               
    柿坂 達彦, 中西 一彰, 横尾 英樹, 蒲池 浩文, 敦賀 陽介, 神山 俊哉, 武冨 紹信
    日本肝胆膵外科学会・学術集会プログラム・抄録集, 24回, 431, 431, (一社)日本肝胆膵外科学会, 2012年05月
    日本語
  • A long-term survival case of adult undifferentiated embryonal sarcoma of liver
    Keita Noguchi, Hideki Yokoo, Kazuaki Nakanishi, Tatsuhiko Kakisaka, Yosuke Tsuruga, Hirofumi Kamachi, Michiaki Matsushita, Toshiya Kamiyama
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 10, 65, 65, 2012年04月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • 血行性転移予防を念頭においた肝細胞癌術後補助化学療法の検討               
    中西 一彰, 神山 俊哉, 横尾 英樹, 柿坂 達彦, 敦賀 陽介, 蒲池 浩文, 武冨 紹信
    肝臓, 53, Suppl.1, A393, A393, (一社)日本肝臓学会, 2012年04月
    日本語
  • Oncologic emergencyとしての下大静脈・右心房浸潤肝細胞癌に対する外科治療               
    中西 一彰, 神山 俊哉, 横尾 英樹, 柿坂 達彦, 敦賀 陽介, 蒲池 浩文, 武冨 紹信
    日本腹部救急医学会雑誌, 32, 2, 408, 408, (一社)日本腹部救急医学会, 2012年02月
    日本語
  • 再肝切除におけるICG蛍光法の使用経験               
    川俣 太, 神山 俊哉, 横尾 英樹, 蒲池 浩文, 田原 宗徳, 柿坂 達彦, 中西 一彰, 松下 通明, 藤堂 省
    IVR: Interventional Radiology, 27, 1, 73, 73, (一社)日本インターベンショナルラジオロジー学会, 2012年02月
    日本語
  • Role of percutaneous transhepatic biliary endoprostheses with distal tube implantation in the subcutaneous space for management of patients with postoperative biliary stricture
    Futoshi Kawamata, Toshiya Kamiyama, Kazuaki Nakanishi, Hideki Yokoo, Tatsuhiko Kakisaka, Munenori Tahara, Hirofumi Kamachi, Michiaki Matsusita, Satoru Todo
    Japanese Journal of Gastroenterological Surgery, 45, 6, 615, 622, 2012年, [査読有り]
    日本語, 研究論文(学術雑誌)
  • 原発性肝癌に対する無水エタノールを用いた術前門脈塞栓術の検討
    柿坂 達彦, 中西 一彰, 横尾 英樹, 敦賀 陽介, 蒲池 浩文, 松下 通明, 神山 俊哉
    北海道外科雑誌, 56, 2, 152, 152, 北海道外科学会, 2011年12月
    日本語
  • 門脈内腫瘍栓を形成した膵管癌の2切除例
    敦賀 陽介, 蒲池 浩文, 柿坂 達彦, 横尾 英樹, 中西 一彰, 松下 通明, 神山 俊哉
    北海道外科雑誌, 56, 2, 155, 155, 北海道外科学会, 2011年12月
    日本語
  • 著明な壁肥厚を呈した劇症型アメーバ性大腸炎の1例
    柿坂 達彦, 相木 総良, 松久 忠史, 服部 淳夫, 古家 乾, 数井 啓蔵
    北海道外科雑誌, 56, 2, 134, 138, 北海道外科学会, 2011年12月
    日本語
  • [Usefulness of intraoperative fluorescent imaging using indocyanine green for repeated resection of hepatocellular carcinoma].
    Yokoo H, Nakanishi K, Kakisaka T, Tsuruga Y, Kawamata F, Kamachi H, Matsushita M, Kamiyama T
    Gan to kagaku ryoho. Cancer & chemotherapy, 38, 12, 2481, 2483, 12, 2011年11月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌), For recurrent hepatic tumors with treatment history or cirrhosis, small region including extrahepatic tumors that cannot be identified on routine ultrasonography, we used a fluorescent imaging with indocyanine green (ICG) for repeated resection of hepatocellular carcinoma. The patients were consisted of 4 men and 2 women with a mean age of 61.5 (37-66) years. Five cases of intra or extra hepatic tumors could be identified with fluorescent imaging system. Two cases were a local recurrence after TACE, 1 case was a small tumor exited in liver surface, 1 case could be identified the area of vascular invasion of subcutaneous recurrence, and 1 case was a mediastinal small lymph node metastasis of hepatocellular carcinoma. Fluorescent imaging using ICG was considered to be useful for identification of recurrent hepatocellular carcinoma that cannot be identified by a routine ultrasonography.
  • 術前の血清検査で診断が困難であった肝エキノコックス症の1例               
    松澤 文彦, 神山 俊哉, 中西 一彰, 横尾 英樹, 柿坂 達彦, 敦賀 陽介, 蒲池 浩文, 松下 通明, 佐藤 直樹
    日本臨床外科学会雑誌, 72, 10, 2739, 2740, 日本臨床外科学会, 2011年10月
    日本語
  • 進行肝細胞癌の治療戦略 高度脈管侵襲陽性肝細胞癌に対する治療戦略               
    中西 一彰, 神山 俊哉, 横尾 英樹, 柿坂 達彦, 敦賀 陽介, 蒲池 浩文, 松下 通明
    日本臨床外科学会雑誌, 72, 増刊, 328, 328, 日本臨床外科学会, 2011年10月
    日本語
  • 手術・そこが知りたい!(肝・胆・膵領域の手術における血行再建術) SMA周囲神経叢郭清に先行して門脈再建を行う膵頭十二指腸切除               
    蒲池 浩文, 敦賀 陽介, 柿坂 達彦, 横尾 英樹, 中西 一彰, 松下 通明, 神山 俊哉
    日本臨床外科学会雑誌, 72, 増刊, 407, 407, 日本臨床外科学会, 2011年10月
    日本語
  • 長期生存を得た成人肝未分化肉腫の1例               
    野口 慶太, 横尾 英樹, 中西 一彰, 柿坂 達彦, 敦賀 陽介, 蒲池 浩文, 松下 通明, 神山 俊哉
    日本臨床外科学会雑誌, 72, 増刊, 620, 620, 日本臨床外科学会, 2011年10月
    日本語
  • vp2肝細胞癌の治療成績と今後の展望               
    横尾 英樹, 神山 俊哉, 中西 一彰, 柿坂 達彦, 敦賀 陽介, 蒲池 浩文, 松下 通明
    日本臨床外科学会雑誌, 72, 増刊, 621, 621, 日本臨床外科学会, 2011年10月
    日本語
  • 再肝切除に伴うICG蛍光法の有用性               
    川俣 太, 神山 俊哉, 横尾 英樹, 中西 一彰, 柿坂 達彦, 敦賀 陽介, 田原 宗徳, 蒲池 浩文, 松下 通明, 藤堂 省
    日本臨床外科学会雑誌, 72, 増刊, 622, 622, 日本臨床外科学会, 2011年10月
    日本語
  • Coombs陰性自己免疫性溶血性貧血に対し、腹腔鏡下脾臓摘出術が奏功した1例               
    松澤 文彦, 神山 俊哉, 中西 一彰, 蒲池 浩文, 横尾 英樹, 敦賀 陽介, 柿坂 達彦, 松下 通明
    日本臨床外科学会雑誌, 72, 増刊, 814, 814, 日本臨床外科学会, 2011年10月
    日本語
  • 肝エキノコックス症に対する腹腔鏡下肝切除術               
    柿坂 達彦, 中西 一彰, 横尾 英樹, 蒲池 浩文, 敦賀 陽介, 松下 通明, 佐藤 直樹, 神山 俊哉
    日本臨床外科学会雑誌, 72, 増刊, 819, 819, 日本臨床外科学会, 2011年10月
    日本語
  • 膵・胆道癌術後門脈狭窄に対し、門脈ステントを留置した3例               
    敦賀 陽介, 蒲池 浩文, 柿坂 達彦, 横尾 英樹, 中西 一彰, 松下 通明, 神山 俊哉
    日本臨床外科学会雑誌, 72, 増刊, 829, 829, 日本臨床外科学会, 2011年10月
    日本語
  • Local skin flap reconstruction for abdominal wound dehiscence after abdominal surgery with a stoma: report of two cases.
    Tatsuhiko Kakisaka, Shigehito Yoneyama, Tomonari Katayama, Takeshi Kikuchi, Kazuhito Uemura, Yoshio Ito, Yoshie Une
    Surgery today, 41, 9, 1252, 4, 2011年09月, [国内誌]
    英語, 研究論文(学術雑誌), Abdominal wound dehiscence is a serious complication of laparotomy, and fascial dehiscence in a patient with a stoma is especially difficult to manage. We describe how we performed local skin flap reconstruction for abdominal wound dehiscence in two patients with stomas. One patient underwent sigmoidectomy with a colostomy for peritonitis caused by perforated diverticulitis of the sigmoid colon. Postoperative fascial dehiscence was repaired by rhomboid flap reconstruction. The other patient underwent total gastrectomy, cholecystectomy, and splenectomy. An ileostomy was performed for digestive tract perforation, which was complicated by abdominal dehiscence with necrosis of the fascia. This was repaired by rotation flap reconstruction. The abdominal walls in both patients were repaired successfully without tension.
  • ミリプラチンを用いたLipiodol-TAI後早期に血流が再開した再発HCC2例               
    松澤 文彦, 神山 俊哉, 中西 一彰, 横尾 英樹, 柿坂 達彦, 田原 宗徳, 谷口 雅彦, 蒲池 浩文, 松下 通明, 藤堂 省, 作原 祐介, 曽山 武志
    IVR: Interventional Radiology, 26, 3, 341, 341, (一社)日本インターベンショナルラジオロジー学会, 2011年08月
    日本語
  • 高度脈管侵襲を伴う肝細胞癌に対する治療戦略 Vp3、4肝細胞癌における術前門脈腫瘍栓に対する放射線照射の有用性               
    神山 俊哉, 中西 一彰, 横尾 英樹, 蒲池 浩文, 田原 宗徳, 柿坂 達彦, 松下 通明, 藤堂 省
    日本消化器外科学会総会, 66回, 200, 200, (一社)日本消化器外科学会, 2011年07月
    日本語
  • 術前肝予備能評価の再考 当科の術前肝予備能評価と肝2区域切除以上の180例の検討(適応拡大に向けた新しい評価方法)               
    田原 宗徳, 神山 俊哉, 柿坂 達彦, 横尾 英樹, 蒲池 浩文, 中西 一彰, 松下 通明, 藤堂 省
    日本消化器外科学会総会, 66回, 257, 257, (一社)日本消化器外科学会, 2011年07月
    日本語
  • 肝胆道癌手術における肝臓外科と胆道外科の接点 左葉系切除を要する肝門部胆管系腫瘍における肝実質切離による右グリソンアプローチ               
    蒲池 浩文, 神山 俊哉, 田原 宗徳, 柿坂 達彦, 横尾 英樹, 中西 一彰, 山下 健一郎, 松下 通明, 藤堂 省
    日本消化器外科学会総会, 66回, 285, 285, (一社)日本消化器外科学会, 2011年07月
    日本語
  • 下大静脈・右心房に進展した肝細胞癌(Vv3)に対する切除治療成績の検討               
    中西 一彰, 神山 俊哉, 横尾 英樹, 柿坂 達彦, 田原 宗徳, 蒲池 浩文, 松下 通明, 藤堂 省
    日本消化器外科学会総会, 66回, 443, 443, (一社)日本消化器外科学会, 2011年07月
    日本語
  • 大腸癌肝転移切除後の治療戦略 再切除可能な術後補助化学療法をめざして               
    横尾 英樹, 神山 俊哉, 中西 一彰, 柿坂 達彦, 田原 宗徳, 蒲池 浩文, 松下 通明, 藤堂 省
    日本消化器外科学会総会, 66回, 557, 557, (一社)日本消化器外科学会, 2011年07月
    日本語
  • 肝エキノコックス症に対する肝切除成績の検討               
    川村 典生, 神山 俊哉, 佐藤 直樹, 中西 一彰, 横尾 英樹, 柿坂 達彦, 蒲池 浩文, 田原 宗徳, 松下 通明, 藤堂 省
    日本消化器外科学会総会, 66回, 643, 643, (一社)日本消化器外科学会, 2011年07月
    日本語
  • 若年者肝細胞癌切除症例における予後因子の検討               
    島田 慎吾, 神山 俊哉, 中西 一彰, 横尾 英樹, 蒲池 浩文, 田原 宗徳, 柿坂 達彦, 松下 通明, 藤堂 省
    日本消化器外科学会総会, 66回, 646, 646, (一社)日本消化器外科学会, 2011年07月
    日本語
  • 大腸癌肝転移切除例の治療成績               
    横尾 英樹, 神山 俊哉, 中西 一彰, 柿坂 達彦, 田原 宗徳, 小丹枝 裕二, 相山 健, 蒲池 浩文, 松下 通明, 藤堂 省
    北海道外科雑誌, 56, 1, 59, 59, 北海道外科学会, 2011年06月
    日本語
  • 大腸穿通により診断に苦慮した肝エキノコックス症の一例               
    相山 健, 神山 俊哉, 中西 一彰, 蒲池 浩文, 横尾 英樹, 田原 宗徳, 柿坂 達彦, 松下 通明, 藤堂 省
    北海道外科雑誌, 56, 1, 60, 60, 北海道外科学会, 2011年06月
    日本語
  • 腹腔内原発のキャッスルマン病の一例               
    川俣 太, 蒲池 浩文, 田原 宗徳, 柿坂 達彦, 横尾 英樹, 中西 一彰, 神山 俊哉, 藤堂 省
    北海道外科雑誌, 56, 1, 67, 68, 北海道外科学会, 2011年06月
    日本語
  • 肝胆膵外科領域で習得すべき血行再建手技(1) 肝門部領域胆管系腫瘍に対する血行再建手技の工夫               
    蒲池 浩文, 神山 俊哉, 田原 宗徳, 柿坂 達彦, 谷口 雅彦, 横尾 英樹, 中西 一彰, 山下 健一郎, 松下 通明, 藤堂 省
    日本肝胆膵外科学会・学術集会プログラム・抄録集, 23回, 195, 195, (一社)日本肝胆膵外科学会, 2011年06月
    日本語
  • 進行肝癌に対する治療戦略と手術の実際 下大静脈・右心房に進展した原発性肝癌に対する外科治療               
    中西 一彰, 神山 俊哉, 横尾 英樹, 柿坂 達彦, 田原 宗徳, 蒲池 浩文, 松下 通明, 藤堂 省
    日本肝胆膵外科学会・学術集会プログラム・抄録集, 23回, 243, 243, (一社)日本肝胆膵外科学会, 2011年06月
    日本語
  • 安全かつ確実な腹腔鏡下肝切除術を目指して(1) 安全かつ確実な腹腔鏡下肝切除術を目指して               
    神山 俊哉, 中西 一彰, 横尾 英樹, 蒲池 浩文, 田原 宗徳, 柿坂 達彦, 谷口 雅彦, 松下 通明, 藤堂 省
    日本肝胆膵外科学会・学術集会プログラム・抄録集, 23回, 256, 256, (一社)日本肝胆膵外科学会, 2011年06月
    日本語
  • 肝切除術の新たな工夫(1) 安全な肝切離をめざして ハーモニックスカルペルとVIO systemのsoft凝固モードを用いたDS3.0による肝切離               
    横尾 英樹, 神山 俊哉, 中西 一彰, 柿坂 達彦, 田原 宗徳, 蒲池 浩文, 松下 通明, 藤堂 省
    日本肝胆膵外科学会・学術集会プログラム・抄録集, 23回, 264, 264, (一社)日本肝胆膵外科学会, 2011年06月
    日本語
  • ニードルガイディングテクニックを用いた系統的亜区域切除術               
    柿坂 達彦, 神山 俊哉, 中西 一彰, 横尾 英樹, 蒲池 浩文, 田原 宗徳, 松下 通明, 藤堂 省
    日本肝胆膵外科学会・学術集会プログラム・抄録集, 23回, 293, 293, (一社)日本肝胆膵外科学会, 2011年06月
    日本語
  • A successful case of systemic chemotherapy followed by liver resection for advanced hepatocellular carcinoma with highly vascular invasion and multiple pulmonary metastases
    Tatsuzo Mizukami, Toshiya Kamiyama, Kazuaki Nakanishi, Masahiko Taniguchi, Hideki Yokoo, Munenori Tahara, Tatsuhiko Kakisaka, Hirofumi Kamachi, Michiaki Matsushita, Satoru Todo
    Japanese Journal of Cancer and Chemotherapy, 38, 5, 849, 852, Japanese Journal of Cancer and Chemotherapy Publishers Inc., 2011年05月15日, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌)
  • 皮膚筋炎を合併した肝細胞癌(HCC)の1例
    石黒 友唯, 神山 俊哉, 中西 一彰, 横尾 英樹, 柿坂 達彦, 田原 宗徳, 谷口 雅彦, 蒲池 浩文, 松下 通明, 藤堂 省
    北海道外科雑誌, 55, 2, 174, 175, 北海道外科学会, 2010年12月
    日本語
  • 広範囲に膵進展を認めた膵頭部癌の1切除例
    島田 慎吾, 蒲池 浩文, 田原 宗徳, 柿坂 達彦, 横尾 英樹, 谷口 雅彦, 中西 一彰, 神山 俊哉, 松下 通明, 藤堂 省
    北海道外科雑誌, 55, 2, 179, 179, 北海道外科学会, 2010年12月
    日本語
  • 術後TS-1投与が奏効した多発肺転移を伴う高度脈管侵襲肝細胞癌の1例               
    水上 達三, 神山 俊哉, 中西 一彰, 谷口 雅彦, 横尾 英樹, 田原 宗徳, 柿坂 達彦, 蒲池 浩文, 松下 通明, 藤堂 省
    日本臨床外科学会雑誌, 71, 10, 2737, 2738, 日本臨床外科学会, 2010年10月
    日本語
  • 当科における安全な肝切除の工夫 術前プランニングと術中操作               
    中西 一彰, 神山 俊哉, 横尾 英樹, 柿坂 達彦, 田原 宗徳, 谷口 雅彦, 蒲池 浩文, 松下 通明, 藤堂 省
    日本臨床外科学会雑誌, 71, 増刊, 425, 425, 日本臨床外科学会, 2010年10月
    日本語
  • 肝門部領域胆管系腫瘍における血管合併切除 左葉系切除におけるプランニングと手技               
    蒲池 浩文, 神山 俊哉, 田原 宗徳, 柿坂 達彦, 福森 大介, 谷口 雅彦, 横尾 英樹, 中西 一彰, 山下 健一郎, 松下 通明, 藤堂 省
    日本臨床外科学会雑誌, 71, 増刊, 461, 461, 日本臨床外科学会, 2010年10月
    日本語
  • 術後胆汁瘻の検討 その原因と対策               
    横尾 英樹, 神山 俊哉, 中西 一彰, 谷口 雅彦, 田原 宗徳, 柿坂 達彦, 蒲池 浩文, 松下 通明, 藤堂 省
    日本臨床外科学会雑誌, 71, 増刊, 533, 533, 日本臨床外科学会, 2010年10月
    日本語
  • 1年以内早期に癌死する肝細胞癌切除症例の検討               
    神山 俊哉, 中西 一彰, 横尾 英樹, 蒲池 浩文, 谷口 雅彦, 田原 宗徳, 柿坂 達彦, 松下 通明, 藤堂 省
    日本臨床外科学会雑誌, 71, 増刊, 546, 546, 日本臨床外科学会, 2010年10月
    日本語
  • 肝切除の術中操作に伴う胆道狭窄に対する皮下植え込み式胆道内瘻法の有用性               
    川俣 太, 神山 俊哉, 中西 一彰, 横尾 英樹, 柿坂 達彦, 田原 宗徳, 谷口 雅彦, 蒲池 浩文, 松下 道明, 藤堂 省
    日本臨床外科学会雑誌, 71, 増刊, 619, 619, 日本臨床外科学会, 2010年10月
    日本語
  • 肝細胞癌術後脳転移症例の検討               
    柿坂 達彦, 神山 俊哉, 中西 一彰, 横尾 英樹, 蒲池 浩文, 田原 宗徳, 谷口 雅彦, 松下 通明, 藤堂 省
    日本臨床外科学会雑誌, 71, 増刊, 729, 729, 日本臨床外科学会, 2010年10月
    日本語
  • 皮膚筋炎を合併した肝細胞癌(HCC)の1例               
    石黒 友唯, 神山 俊哉, 中西 一彰, 横尾 英樹, 柿坂 達彦, 田原 宗徳, 谷口 雅彦, 蒲池 浩文, 松下 通明, 藤堂 省
    日本臨床外科学会雑誌, 71, 増刊, 730, 730, 日本臨床外科学会, 2010年10月
    日本語
  • 門脈腫瘍栓を伴った退形成性膵癌の一例               
    田原 宗徳, 蒲池 浩文, 柿坂 達彦, 横尾 英樹, 中西 一彰, 神山 俊哉, 松下 通明, 藤堂 省
    日本臨床外科学会雑誌, 71, 増刊, 791, 791, 日本臨床外科学会, 2010年10月
    日本語
  • A case of metachronous multiple lung metastases and intraabdominal lymph node metastases of rectal cancer responding to S-1
    Tatsuhiko Kakisaka, Fusayoshi Aiki, Tadashi Matsuhisa, Atsuo Hattori, Keizou Kazui
    Japanese Journal of Cancer and Chemotherapy, 37, 4, 723, 725, Japanese Journal of Cancer and Chemotherapy Publishers Inc., 2010年04月06日, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌)
  • A study of cirrhotic patients with hepatocellular carcinoma and huge splenomegaly who received treatment for hepatocellular carcinoma with concomitant splenectomy
    Takeshi Aiyama, Toshiya Kamiyama, Kazuaki Nakanishi, Hideki Yokoo, Masahiko Taniguchi, Daisuke Fukumori, Munenori Tahara, Tatsuya Kakisaka, Hirofumi Kamachi, Michiaki Matsushita, Satoru Todo
    Japanese Journal of Cancer and Chemotherapy, 37, 12, 2683, 2686, Japanese Journal of Cancer and Chemotherapy Publishers Inc., 2010年, [査読有り]
    日本語, 研究論文(学術雑誌)
  • Proteomic Profiling Reveals the Prognostic Value of Adenomatous Polyposis Coli-End-Binding Protein 1 in Hepatocellular Carcinoma
    Tatsuya Orimo, Hidenori Ojima, Nobuyoshi Hiraoka, Shigeru Saito, Tomoo Kosuge, Tatsuhiko Kakisaka, Hideki Yokoo, Kazuaki Nakanishi, Toshiya Kamiyama, Satoru Todo, Setsuo Hirohashi, Tadashi Kondo
    HEPATOLOGY, 48, 6, 1851, 1863, 2008年12月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): Up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer
    Tatsuhiko Kakisaka, Tadashi Kondo, Tetsuya Okano, Kiyonaga Fujii, Kazufumi Honda, Mitsufumi Endo, Akihiko Tsuchida, Tatsuya Aoki, Takao Itoi, Fuminori Moriyasu, Tesshi Yamada, Harubumi Kato, Toshihide Nishimura, Satoru Todo, Setsuo Hirohashi
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 852, 1-2, 257, 267, 2007年06月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • 【呼吸器と寄生虫】肺の多包性エキノコックス症
    佐藤 直樹, 寺崎 康展, 佐々木 彩実, 柿坂 達彦, 横尾 英樹, 山下 健一郎, 中西 一彰, 嶋村 剛, 神山 俊哉, 松下 通明, 藤堂 省
    日本胸部臨床, 66, 4, 289, 296, 克誠堂出版(株), 2007年04月
    日本語
  • Hepatopulmonary fistula caused by alveolar echinococcosis: Report of a case
    Tatsuhiko Kakisaka, Naoki Sato, Toshiya Kamiyama, Takahito Nakagawa, Takahito Nakagawa, Kazuaki Nakanishi, Michiaki Matsushita, Tomoo Ito, Satoru Todo
    SURGERY TODAY, 36, 10, 937, 940, 2006年10月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌)
  • Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis
    Tetsuya Okano, Tadashi Kondo, Tatsuhiko Kakisaka, Kiyonaga Fujii, Masayo Yamada, Harubumi Kato, Toshihide Nishimura, Akihiko Gemma, Shoji Kudoh, Setsuo Hirohashi
    PROTEOMICS, 6, 13, 3938, 3948, 2006年07月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • 多次元クロマトグラフィーと二次元電気泳動法を用いた膵がんの血漿プロテオミクス
    柿坂 達彦, 近藤 格, 岡野 哲也, 藤井 清永, 西村 俊秀, 藤堂 省, 廣橋 説雄
    日本プロテオーム学会大会要旨集, 2005, 137, 137, 日本プロテオーム学会(日本ヒトプロテオーム機構), 2005年
    【背景】膵がんは早期発見が困難であるため手術不能例が多く予後不良な疾患である。早期に膵がんを診断できる鋭敏かつ特異的な腫瘍マーカーが求められている。本研究では膵がん患者の血漿を用い,プロテオーム解析の手法によって,膵がんにおいて発現ならびに翻訳後修飾の異常が認められる血漿タンパク質群を同定した。
    【方法】国立がんセンター中央病院を受診した膵がん患者の血漿(n = 5)とボランティアの血漿(n = 5)を使用した。Multiple Affinity Removal Column(Agilent社)を用い,血漿から高容量タンパク質を取り除き低容量タンパク質画分(FT)を得た。 さらにFTを陰イオン交換カラムで5画分に分けた。全血漿,FTは個々人のサンプルで二次元電気泳動を行い,陰イオン交換カラムで分けたサンプルはそれぞれの分画で膵がん患者,ボランティアごとに混合し,二次元電気泳動を行った。二次元電気泳動の方法としては,2D-DIGE(two-dimensional difference gel electrophoresis)法を用いた。膵がん患者とボランティアで2倍以上発現量が変化しているスポットを,画像解析ソフトを用いて検索した。統計学的手法はStudent's t-testを使用し,p<0.01を有意とした。有意に発現量が変化しているスポットは質量分析にてタンパク質を同定した。
    【結果】全血漿の二次元電気泳動では290スポットが観察されたが,高容量タンパク質を除いたFTでは403スポットに増加した。さらに陰イオン交換カラムを使用することで観察可能なタンパク質が合計1098スポットに増加した。この増加は分画によりタンパク質サンプルの複雑度を減少させたことによるものと考えられる。膵がん患者において有意に発現量が変化しているスポットが39スポット同定され,質量分析にてタンパク質を同定した。
    【結論】多次元液体クロマトグラフィーと二次元電気泳動法を組み合わせた手法は血漿のプロテオーム解析において有効な方法である。同定されたタンパク質は膵がんの腫瘍マーカーとして有用なだけでなく,膵がんの病態の理解にもつながる可能性がある。
  • 旭川厚生病院外科手術集計-2002年報               
    赤羽 弘充, 高橋 昌宏, 中野 詩朗, 稲垣 光裕, 河田 聡, 安原 満夫, 青木 貴徳, 野村 克, 横尾 英樹, 唐崎 秀則, 柿坂 達彦, 青柳 武史, 小片 武, 山田 理大, 宇野 元博, 尾崎 篤子, 斉藤 芳儀, 菊地 信明, 菅原 かおり, 柳田 翼, 橋本 晃佳
    旭川厚生病院医誌, 13, 1, 62, 66, 旭川厚生病院, 2003年06月
    日本語
  • 異時性肝転移をきたした直腸カルチノイドの1例               
    柿坂 達彦, 中野 詩朗, 尾崎 篤子, 宇野 元博, 唐崎 秀則, 野村 克, 青木 貴徳, 安原 満夫, 赤羽 弘充, 船井 哲雄, 高橋 昌宏
    旭川厚生病院医誌, 12, 2, 106, 109, 旭川厚生病院, 2002年12月
    日本語

その他活動・業績

共同研究・競争的資金等の研究課題

  • 消化器がんに対するDGKα/ζを標的とした核酸医薬による新規免疫療法の開発研究
    科学研究費助成事業 基盤研究(B)
    2022年04月01日 - 2025年03月31日
    武冨 紹信, 北村 秀光, 柿坂 達彦, 深井 原
    日本学術振興会, 基盤研究(B), 北海道大学, 22H03142
  • 血中exosome内circRNA発現解析による膵癌の診断・予後関連マーカー探索
    科学研究費助成事業 基盤研究(C)
    2022年04月01日 - 2025年03月31日
    柿坂 達彦, 蒲池 浩文, 長田 直樹, 神山 俊哉, 折茂 達也
    日本学術振興会, 基盤研究(C), 北海道大学, 22K08789
  • 切除検体を基にした網羅的糖鎖解析による肝細胞癌悪性度解析と新規バイオマーカー開発
    科学研究費助成事業 基盤研究(C)
    2021年04月01日 - 2024年03月31日
    神山 俊哉, 西村 紳一郎, 旭 火華, 坂本 譲, 柿坂 達彦, 折茂 達也, 長津 明久
    これまでの糖鎖解析を行う癌に関する研究は、患者血清を用いるものが多かったが、患者背景:併存する疾患、人種などの影響があり、癌細胞上で行われる糖鎖修飾がどのように癌細胞の生物学的な悪性度を関連性があるかは未解決である。肝癌細胞株での実験で、これまで報告された患者血清から検出された糖鎖と異なるものが、浸潤能に関与していることが分かったため、実際の切除検体である癌細胞組織での検討が必要であるとの考えに至った。
    今年度は、実際の切除検体である癌細胞組織での糖鎖解析による検討を行った。2001年から2006年までの肝細胞癌切除例48例の凍結検体の網羅的糖鎖解析による糖鎖発現を全自動血清糖鎖プロファイル解析で行った。1325.55m/zから3336.24m/zまでの39個の糖鎖を検出でき、肝癌組織のN型糖鎖プロファイルを解析できた。凍結保存された肝細胞癌切除標本の糖鎖解析が普遍的に可能であることが検証された。今後、同一患者さんで、非癌部の肝組織、血清での発現と、今回検出できた糖鎖との関連性を検証していく。さらにこれらの結果と臨床病理学的所見・組織病理学的所見、切除後の予後・再発との関連性を検討する予定であり、実際の肝細胞癌組織と癌悪性度、浸潤能などとの関連性がある特異の糖鎖が発見され、この糖鎖修飾を阻害することができる阻害剤が見つかれば、創薬の点からも癌治療に大きく貢献できると確信している。肝切除かあるいは分子標的薬による薬物治療かの治療選択基準となりうる新規バイオマーカーを検出できる可能性がある。
    日本学術振興会, 基盤研究(C), 北海道大学, 21K07210
  • 血漿タンパク質LRGの翻訳後修飾に着目した膵癌早期診断マーカーの解析
    科学研究費助成事業 若手研究(B)
    2014年04月01日 - 2018年03月31日
    柿坂 達彦
    早期診断が困難で予後不良な疾患である膵癌患者の血清を使用して、leucine-rich alpha-2-glycoprotein (以下LRG)が診断マーカーをなり得るかを検討した。膵癌患者68例、健常者10例の血清を使用し、ELISAによりLRGの発現量を検討した結果、健常者と比較して膵癌患者において有意にLRG値が高値であった。ステージ0-Ⅱの症例でも健常者より高値を呈していた。さらにCA19-9が陰性の膵癌患者25症例中22例でLRGが高値を示しており、膵癌診断マーカーとしての可能性が示唆された。今後、LRGを血清から単離して、LRGに結合している糖鎖解析を行う予定である。
    日本学術振興会, 若手研究(B), 北海道大学, 26870002
  • 新規バイオマーカーAPC結合蛋白EB1の肝細胞癌発癌進展における分子機構の解明
    科学研究費助成事業 基盤研究(C)
    2013年04月01日 - 2016年03月31日
    中西 一彰, 横尾 英樹, 柿坂 達彦, 神山 俊哉, 武冨 紹信, 折茂 達也, 福原 嵩介, 大畑 多嘉宣, 高橋 秀徳, 小林 希, 三好 早香, 堀米 正敏
    以前にAdenomatous polyposis coli結合蛋白EB1(以下EB1)が肝細胞癌で高発現していることを報告した。今回の研究で、①初発肝細胞癌根治切除症例においてEB1の発現は分化度、AFP、門脈浸潤と有意な相関関係を示し、EB1高発現群では全生存率が有意に不良であり、再発率も有意に高かった(各P<0.0001)。②肝癌細胞株においてEB1の発現を変動させると、細胞の増殖能・遊走能・浸潤能・腫瘍増殖能がパラレルに変動した。③マイクロアレイ解析においてEB1はDlk-1の発現を制御している可能性が示唆された。以上より、EB1は新規バイオマーカーとして有用であると考える。
    日本学術振興会, 基盤研究(C), 北海道大学, 25430134
  • 肝細胞癌悪性度バイオマーカー候補E-FABPの発現、機能解析
    科学研究費助成事業 基盤研究(C)
    2011年 - 2013年
    横尾 英樹, 神山 俊哉, 中西 一彰, 柿坂 達彦
    肝細胞癌切除検体に対し免疫組織化学染色を施行、FABP5高発現をしている肝癌細胞株に対しRNAi法を用い増殖能、浸潤能の差を検討した。予後、再発の検討では5年でOSがFABP5-群で89.9%、FABP5+群で59.5%と2群間で有意差を認め(p<0.0001)、肝癌細胞株においては、RNAi群がcontrol群と比較して増殖能、浸潤能の低下を認めた(p<0.05)。肝細胞癌におけるFABP5の発現は予後、再発、腫瘍の悪性度に非常に強い相関性を示しており、肝細胞癌の新たなバイオマーカー、新しい治療のターゲット分子として強く期待される。
    日本学術振興会, 基盤研究(C), 北海道大学, 23501293